 
  
Study Title EVALUATION  OF SAFETY OF REPEATED  DOSES OF OP0201 METERED  DOSE 
INHALER COMPARED  TO PLACEBO  IN HEALTHY ADULT VOLUNTEERS  
NCT Number [STUDY_ID_REMOVED]  
Document  Description  Clinical Protocol, Amendment  1 
Document  Date 09 October 2018 
 

CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 1 TITLE PAGE 
Protocol Title:  
Evaluation of safety of repeated doses of OP0201 mete red dose inhaler compared to placebo in healthy 
adult volunteers. 
Protocol Number: OP0201-C-002  
Amendment Number: Amendment 1  
Product: OP0201 metered dose inhaler  
Study Phase: 1 
Sponsor Name: Novus Therapeutics, Inc.  
Legal Registered Address: 19900 MacArthur, Suite 550, Irvine, California 92612, United States (US)  
 Regulatory Agency Identifying Number: IND 106778  
 
Date of Protocol: 09 October 2018  
  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 2 Sponsor Signatory: 
  
I have read this protocol in its entiret y and agree to conduct the study accordingly: 
  
xxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx  Date 
 
 
    
 
 Medical Monitor name and contact information can be found in Appendix 2 . 
  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 3 PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE 
Table 1 Document History 
Document Date Substantial Region 
Amendment 1 09 October 2018 Yes US 
Original Protocol 17 July 2018 - - 
 
Amendment 1 (09 October 2018) 
Overall Rationale for the Amendment:  
During creation of the electronic case repor t forms (eCRFs) on otoscopy assessment, a 
discrepancy was noted in the way the assessments are described in the eCRF versus the protocol.  
It was thus decided to amend th e description in the protocol to  match the eCRF.  Additionally, 
during the eCRF creation, update s to the section on nasal and epipharynx endoscopy, and 
audiology pure tone hearing test was also updated in the protocol .  Moreover, discussions with 
IQVIA biostatisticians and the st udy center led to the update of the randomization procedure, the 
number of days residency in the study center and clarity on assessments to  be performed in the 
case of early termination of the study.  Due to logistical reas ons, the telephonic study exit visit at 
Day 30 was removed and Day 21 will now be the study exit visit. 
Table 2 Description of Changes in Amendment 
Section # and 
Name Description of Change Brief Rationale 
Synopsis – 
Overall design, 
Section 4.1 
Study Design 
and Section 
6.3.1 Study Treatment Kit Removal of stratification by gender. Per the protocol, randomization is to be stratified 
by gender within each of the 2 cohorts (Cohorts A 
and B) and subjects are to be randomized in 4:1 
ratio to active:placebo within each cohort.  After 
further discussion with IQVIA biostatisticians and 
the Sponsor, it was agreed that gender stratification within a 4:1 randomization scheme 
would be problematic.  Thus, gender stratification 
is removed from the protocol.  
Section 1.3 Schedule of Activities Addition of early termination (EaT) 
assessments to align with the Day 21 study exit visit. Per the protocol, no assessments are specified for 
cases where a subject has been treated but wants 
to discontinue early from the study.  IQVIA, in 
consultation with the Sponsor, discussed and agreed that as a standard, when subjects 
discontinue early, if possible, they should 
complete all study procedures required at the stuidy exit vist.  Thus, the protocol has been amended to reflect this. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 4 Section # and 
Name Description of Change Brief Rationale 
Synopsis – 
Overall design, 
Section 1.2 Schema, 
Section 1.3 
Schedule of Activities and 
Section 4.1 
Study Design Removal of the option for subjects to 
leave the study center on the evening of 
Day 14 after all the assessments have been completed. Previously, the protocol gave the option for 
subjects to leave the study center on Day 14 after 
all the assessments have been completed.  However, in consultation with the study center it 
was decided that the timing of the last dose 
administration on Day 14 (23:00) was too late and that most subjects would opt to stay the night and 
leave the study center on the morning of Day 15.  
The protocol has been amended to reflect this. 
Synopsis – 
Overall design, 
Section 1.2 Schema, 
Section 1.3 
Schedule of Activities and 
Section 4.1 
Study Design The telephonic study exit visit at Day 30 
was removed and Day 21 will now be 
the study exit visit. Due to logistical reasons,  and the fact that the 
drug is short acting with no known or projected 
long-term adverse events, the follow-up period was shortened. 
Synopsis, Number of Subjects Number of subject to be screened 
changed from 35 to 60. The study center will use a 1:1 screen fail ratio. 
Therefore, up to 60 subjects will be screened to enroll 30. 
Section 1.3 Schedule of Activities and 
Section  6.1 
Study Treatment(s) Administered Schedule of dose administration 
changed to every 7 hours, ie, a morning dose at 9:00 am, an afternoon dose at 
16:00 pm and an evening dose at 23:00 
pm. Due to logistical reason s at the study center. 
Section 1.3 
Schedule of 
Activities and 
Section 8.2.7 Nasal and 
Epipharynx 
Endoscopy Amend the protocol to allow for all pre-
dose ear, nose and throat (ENT) 
procedures to be completed on Day -1 
instead of Day 1.  
Removal of footnote for performing 
scoping within 4 hours of pre-dose on 
all other days so that there isn’t a time constraint. Due to logistical reason s at the study center as 
there will not be enough time to complete the ENT procedures on this day within window.  
 
Synopsis, 
Objectives and 
Endpoints, Section 3.0 Plasma replaced with serum. The table of endpoints was in error and listed 
plasma istead of serum as the detection matrix for 
biomarker analysis. 
Section 5.2 
Exclusion 
Criteria Addition of exclusion criteria: “History 
of drug abuse or positive drug screening 
test at Screening or Day -1 prior to randomization”. Previously a urine drug screen was included in 
the Schedule of Activities, but no corresponding 
exclusion criteria existed. 
Section 8.2.5 Otoscopy Update to otoscopy assessments by 
removing mention of translucency and 
addition of colors to the section Based on the update to the eCRFs regarding the 
otoscopy assessment, it was decided to update 
Section 8.2.5 of the protocol so that it matches the 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 5 Section # and 
Name Description of Change Brief Rationale 
preregarding the color of fluid behind 
the tympanic membrane. way this procedure will be conducted and how the 
data will be collected. 
Section 8.2.7 Nasal and Epipharynx Endoscopy Updated assessments to be made when 
abnormal endoscopy is reported; additional criteria includes: swelling, 
redness, bleeding, rhinorrheoea (nose 
only) and other. Based on the update to the eCRFs regarding the 
nasal and epipharynx endoscopy assessment, it was decided to update Section 8.2.7 of the 
protocol so that it matches the way this procedure 
will be conducted and how the data will be collected. 
Section 8.2.9 Audiology Pure Tone Hearing 
Test and 
Appendix 10 Audiology 
Testing 
Template Section 8.2.9 updated to refer to new 
Audiology Testing Template in Appendix 10 The Audiology Testing Template provided by the 
study center was used to develop the eCRF page.  The template is attached as a sample source for reference. 
Appendix 3, Table 8 Duplication of potassium and 
urea/blood urea nitrogen corrected. Study center noticed duplication of potassium and 
urea in Table 8. 
  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 6 TABLE OF CONTENTS 
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE ................................3  
TABLE OF TABLES ............................................................................................................... 9 
TABLE OF FIGURES .............................................................................................................9  
1.0 PROTOCOL SUMMARY ........................................................................................10  
1.1 Synopsis ...........................................................................................................10  
1.2 Schema ............................................................................................................14  
1.3 Schedule of Activities .....................................................................................15  
2.0 INTRODUCTION......................................................................................................18  
2.1 Study Rationale ..............................................................................................18  
2.2 Background ....................................................................................................18  
2.3 Benefit/Risk Assessment ................................................................................19  
3.0 OBJECTIVES AND ENDPOINTS ..........................................................................21  
4.0 STUDY DESIGN ........................................................................................................22  
4.1 Overall Design ................................................................................................22  
4.2 Scientific Rationale for Study Design ...........................................................23  
4.3 Justification for Dose .....................................................................................23  
4.4 End of Study Definition .................................................................................25  
4.5 Dose-Escalation Criteria ...............................................................................25  
4.6 Study Stopping Criteria ................................................................................25  
4.6.1 Stopping Criteria for Individual Subjects ..........................................25  
4.6.2 Criteria for Stopping Dose-Escalation ...............................................25  
4.6.3 Criteria for Stopping the Study ..........................................................25  
5.0 STUDY POPULATION ............................................................................................27  
5.1 Inclusion Criteria ...........................................................................................27  
5.2 Exclusion Criteria ..........................................................................................28  
5.3 Lifestyle Considerations ................................................................................30  
5.3.1 Meals and Dietary Restrictions .........................................................30  
5.3.2 Caffeine and Alcohol .........................................................................30  
5.3.3 Activity ..............................................................................................30  
5.4 Screen Failures ...............................................................................................31  
6.0 STUDY TREATMENT .............................................................................................32  
6.1 Study Treatment(s) Administered ................................................................32  
6.2 Preparation/Handling/St orage/Accountability ...........................................33  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 7 6.3 Measures to Minimize Bias: Ra ndomization and Blinding........................33  
6.3.1 Study Treatment Kit ..........................................................................33  
6.3.2 Blinding .............................................................................................34  
6.3.3 Procedures for Unblinding Study Treatment .....................................34  
6.4 Study Treatment Compliance .......................................................................34  
6.4.1 Treatment Strategy for Emergencies .................................................34  
6.4.2 Warnings and Precautions .................................................................35  
6.5 Concomitant Therapy ....................................................................................35  
6.6 Dose Modification ..........................................................................................35  
6.7 Treatment After the End of the Study .........................................................35  
7.0 DISCONTINUATION OF STUDY TREATMENT AND SUBJECT 
DISCONTINUATION/WITHDRAWAL ................................................................36  
7.1 Discontinuation of Study Treatment ............................................................36  
7.2 Subject Discontinuation/Withdr awal from the Study ................................36  
7.3 Lost to Follow-up ...........................................................................................37  
8.0 STUDY ASSESSMENTS AND PROCEDURES ....................................................38  
8.1 Efficacy Assessments .....................................................................................38  
8.2 Safety Assessments .........................................................................................38  
8.2.1 Physical Examinations .......................................................................38  
8.2.2 Vital Signs .........................................................................................39  
8.2.3 Electrocardiograms ............................................................................39  
8.2.4 Clinical Safety Laboratory Assessments ...........................................40  
8.2.5 Otoscopy ............................................................................................40  
8.2.6 Tympanometry ..................................................................................40  
8.2.7 Nasal and Epipharynx Endoscopy .....................................................41  
8.2.8 Olfactory Test ....................................................................................41  
8.2.9 Audiology Pure Tone Hearing Test ...................................................42  
8.3 Adverse Events ...............................................................................................42  
8.3.1 Time Period and Frequency for Collecting AE and SAE 
Information ........................................................................................43  
8.3.2 Method of Detecting AEs and SAEs .................................................43  
8.3.3 Follow-up of AEs and SAEs .............................................................43  
8.3.4 Regulatory Reporting Requirements for SAEs .................................43  
8.3.5 Pregnancy ..........................................................................................44  
8.3.6 Adverse Events of Special Interest ....................................................44  
8.3.7 Medical Device Incidents (Including Malfunctions) .........................45  
8.4 Treatment of Overdose ..................................................................................46  
8.5 Pharmacokinetics ...........................................................................................47  
8.5.1 Collection of Samples ........................................................................47  
8.5.2 Determination of Drug Concentration ...............................................47  
8.5.3 Calculation of Derivation of Pharmacokinetic Variables ..................47  
8.6 Pharmacodynamics ........................................................................................48  
8.7 Genetics ...........................................................................................................48  
8.8 Biomarkers .....................................................................................................48  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 8 8.9 Health Economics...........................................................................................48  
9.0 STATISTICAL CONSIDERATIONS .....................................................................48  
9.1 Statistical Hypotheses ....................................................................................48  
9.2 Sample Size Determination ...........................................................................48  
9.3 Populations for Analyses ...............................................................................49  
9.4 Statistical Analyses.........................................................................................49  
9.4.1 Efficacy Analyses ..............................................................................49  
9.4.2 Pharmacokinetic Analyses .................................................................50  
9.4.3 Safety Analyses .................................................................................50  
9.4.4 Missing Data ......................................................................................50  
9.5 Interim Analyses ............................................................................................50  
9.6 Safety Review Committee ..............................................................................51  
10.0 REFERENCES ...........................................................................................................52  
11.0 APPENDICES ............................................................................................................54  
Appendix 1  Abbreviations ...................................................................................55  
Appendix 2  Regulatory, Ethical, and Study Oversight Considerations ..........57  
Regulatory and Ethical Considerations ............................................................57  
Adequate Resources .........................................................................................57  
Financial Disclosure .........................................................................................58  
Insurance ..........................................................................................................58  
Informed Consent Process ...............................................................................58  
Data Protection.................................................................................................58  
Administrative Structure ..................................................................................59  
Medical Monitor ..............................................................................................59  
Dissemination of Clinical Study Data ..............................................................59  
Data Quality Assurance ...................................................................................59  
Source Documents ...........................................................................................60  
Study and Study Center Closure ......................................................................60  
Publication Policy ............................................................................................61  
Appendix 3  Clinical Laboratory Tests ...............................................................62  
Appendix 4  Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting .....................................64  
Appendix 5  Excluded Medications/Therapy .....................................................69  
Appendix 6  Contraceptive Guidance and Collection of Pregnancy 
Information .....................................................................................................70  
Appendix 7  Device Experience Questionnaire ..................................................74  
Appendix 8  Liver Safety: Suggested Actions and Follow-up 
Assessments ....................................................................................................76  
Appendix 9  Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow-up, and Reporting .....................................77  
Appendix 10  Audiology Testing Template ...........................................................79  
Appendix 11  Protocol Amendment History .........................................................80  
Appendix 12  Signature of Investigator ................................................................81 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 9 TABLE OF TABLES 
Table 1  Document History ..............................................................................................3  
Table 2  Description of Changes in Amendment .............................................................3  
Table 3  Schedule of Activities ......................................................................................15  
Table 4  Study Objectives and Endpoints ......................................................................21  
Table 5  Dose Cohorts and Dose Regimen ....................................................................22  
Table 6  Serum Blood Pharmacoki netic Parameters ......................................................48  
Table 7  Analysis Sets ....................................................................................................49  
Table 8  Protocol-required Safety Laboratory Assessments ..........................................62  
 
 
TABLE OF FIGURES 
Figure 1  Study Schema...................................................................................................14  
 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 10 1.0 PROTOCOL SUMMARY 
1.1 Synopsis 
Protocol Title:  
Evaluation of safety of repeated doses of OP0201 mete red dose inhaler compared to placebo in healthy 
adult volunteers 
Rationale: 
OP0201 metered dose inhaler (MDI) (referred herein si mply as OP0201) is a novel, intranasal drug device 
surfactant product being developed by Novus Therapeuti cs, Inc., for the treatment and prevention of otitis 
media (OM).  To date, there is no drug product that has been approved to treat or prevent OM.  
OP0201 is comprised of a 20:1 fixed combinati on of dipalmitoylphosphatidylcholine (DPPC; a 
phospholipid surfactant) and cholesteryl palmitate  (CP; a neutral phospholipid spreading agent) 
suspended in propellant (HFA 134a).  There are no othe r ingredients (ie, no excipients, no fillers) in the 
formulation other than the active ingredients and th e propellant.  None of these ingredients contain any 
animal or human derivatives.  Both DPPC and CP are highly endogenous surfactants in humans, 
including the Eustachian tube (ET), nasopharynx an d respiratory system.  The drug product will be 
delivered as a local treatment through each nostril us ing a metered dose inhalation device. It will be 
sprayed directly backwards into each nostril by way of  the anterior nostrils (not upwards towards the 
osteomeatal opening to the maxillary and ethmoid sinuses as other common intranasal products) towards 
the lateral wall of the nasal cavity so that the usual nasal mucocilia ry clearance pathway can facilitate 
delivery of the drug to the ET.   
This Phase 1 safety study is designed to evaluate the safety and tolerability of daily intranasal OP0201 use 
for 14 consecutive days in 30 healthy adults.  The study will be randomized, double-blind, 
placebo-controlled, parallel-group, and includes a dose- escalation cohort design with evaluation of 30 mg 
per day (Cohort A) and 60 mg per day (Cohort B) of OP0201.   
For more information about OP0201, please refer to the most recent Investigator’s Brochure (IB). 
 Objectives and Endpoints 
Objectives Endpoints 
Primary  
 To evaluate the safety and tolerability of OP0201 
30 mg per day (given as 2 sprays per nostril 3 times a day [TID] for 14 consecutive days) and 
OP0201 60 mg per day (given as 4 sprays per 
nostril TID for 14 consecutive days) compared to 
0 mg placebo (HFA-134a on ly) administered in a 
similar parallel-group fashion TID for 14 consecutive days in healthy adult volunteers.  Adverse events (AEs), otoscopy, tympanometry, 
nasal and epipharynx endoscopy, University of Pennsylvania Smell Inventory Test (UPSIT) 
olfactory test, audiology pure tone hearing test, 
triplicate 12-lead electrocardiogram (ECG), 
physical examination, vital signs, and clinical 
laboratory tests.   
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 11 Secondary/Exploratory  
 To evaluate if any systemic exposure of DPPC can 
be detected in serum at levels higher than 
endogenous DPPC levels in serum in up to 
15 healthy adult volunteers who will be evaluated in the Cohort B dose (OP0210 60 mg per day) versus placebo. 
 To evaluate if any systemic exposure of CP can be 
detected in serum at levels higher than endogenous 
CP levels in serum in up to 15 healthy adult volunteers who will be evaluated in the Cohort B dose (OP0210 60 mg per day) versus placebo.  Maximum baseline adjusted serum concentration 
(C
max) of DPPC on Day 14. 
 Time to maximum concentration (t max) of DPPC 
on Day 14. 
 Maximum baseline adjusted serum concentration 
(Cmax) of CP on Day 14. 
 Time to maximum concentration (t max) of CP on 
Day 14. 
 Additional parameters may be calculated, if 
appropriate. 
 
Overall Design: 
This is a randomized, double-blind, placebo-controlle d, parallel-group, dose-escalation study in healthy 
volunteers to evaluate the safety and tolerability of  OP0201 administered intranasally TID using a MDI 
compared to a matching placebo (HFA 134a minus ac tive ingredients) administered intranasally TID 
using a MDI for 14 consecutive days.  The plan is to  enroll up to 30 subjects at 1 study center in the 
United States.  Two dose cohorts are planned (Cohor t A and Cohort B; N=15 per cohort).  Within each 
cohort, subjects will be randomized in a 4:1 ratio to  receive either OP0201 or placebo.  After all subjects 
in Cohort A have completed the Day 14 visit, a Sa fety Review Committee (SRC) will review all the 
blinded safety data to determine whether the doses ad ministered are safe and well tolerated.  The SRC 
will make a recommendation to escalate to the next cohort (Cohort B) or not. 
Potential subjects will be screened for eligibility dur ing a screening period (Days -28 to -1).  Eligible 
healthy volunteers will be admitted to the study cente r on Day -1 and be randomized on Day -1.  Subjects 
will remain resident at the study center until after a ll the Day 15 assessments have been completed, with a 
study exit visit at Day 21. 
Study treatment will be administered to the subject s by the study center staff TID for 14 days while 
resident at the study center.   
The estimated duration of participation in the study for each subject is up to 54 days: Screening (Days -28 
to -1), treatment (Day 1), 16-day residency (Days -1 to 15 with safety assessments at Days 4, 8, 14, 
and 15), study exit (Day 21 [+5 days]).  No effi cacy assessments will be performed for this study. 
Number of Investigators and Study Centers: Approximately 1 Investigator and study center are expected to participate in this study.  
Number of Subjects: 
Approximately 60 subjects will be screened to achie ve 30 subjects randomly assigned to study treatment 
and 30 evaluable subjects for a total of 15 evaluabl e subjects per treatment group.  Additional subjects 
may be screened to ensure a total of 15 evaluabl e subjects per treatment group.  Subjects who are 
discontinued from the study may be replaced  based on the Sponsor’s discretion. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 12 Treatment Groups and Duration: 
Cohort Dose Regimen Cohort Dose Allocation 
Total 
Subjects in 
Each Cohort Total Subjects 
Per Dose 
Group 
Per Day Total Dose (mg) Cumulative Total Dose (mg) 
A 2 sprays per 
nostril TID × 14 
days 
 OP0201 (30 mg)a 
 
Placebo (0 mg) 
 OP0201 (420 mg) a 
 
Placebo (0 mg) 
 15 N=12 
(OP0201) 
N=3 (Placebo) 
B 4 sprays per 
nostril TID × 14 
days 
 OP0201 (60 mg) a 
 
Placebo (0 mg) 
 OP0201 (840 mg) a 
 
Placebo (0 mg) 
 15 N=12 
(OP0201) 
N=3 (Placebo) 
a 2.5 mg per spray 
N = number of subjects 
Statistical Methods: 
Sample Size Determination  
The sample size is not based on statistical considerations , but is typical for studies of this nature, and is 
considered adequate to characterize the distribution of the planned endpoints. 
There will be a total of 30 subjects; 2 dose cohorts of  15 subjects each.  Subjects will be randomized in 
4:1 (OP0201:placebo) ratio to receive eith er OP0201 or placebo within each dose cohort. 
Populations for Analyses 
Entered Analysis Set All subjects w ho sign the informed consent form. 
Safety Analysis Set All subjects who receive a ny study treatment (OP0201 or placebo). Subjects will 
be analyzed according to the treatment they received. 
Pharmacokinetic (PK) Analysis Set All subjects in  Cohort B who received at least 1 dose of OP0201 
and have 1 quantifiable serum DPPC or CP concentr ation collected post-dose without important protocol 
deviations/violations or events thought to  significantly affect the pharmacokinetics. 
Statistical Analyses 
The Statistical Analysis Plan (SAP) will be deve loped and finalized before database lock and will 
describe the subject analysis sets to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the 
primary and secondary endpoints. 
All analyses (with the exception of PK parameter anal ysis), summaries, and listings will be performed 
using SAS software (Version 9.4 or higher). 
Pharmacokinetic Analyses 
Pharmacokinetic analyses will be described in the SAP that will be finalized before database lock. All PK 
analyses will be performed on the PK Analysis Set. 
Observed and baseline adjusted serum  DPPC concentrations will be summarized by time point.  Observed 
and baseline adjusted serum CP concentrations (if available) will be summarized by time point 
Serum DPPC PK parameters (if any) will be summarized .  Serum CP PK parameters (if available) will be 
summarized. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 13 Safety Analyses 
All safety analyses will be performed on the Safety Analysis Set. 
Treatment-emergent adverse events (TEAEs) are defi ned as AEs that first occurred or worsened in 
severity after administration of study treatment. 
Adverse events will be coded using the Medical Di ctionary for Regulatory Activities (MedDRA). For 
each study treatment, numbers of TEAEs and incidenc e rates will be tabulated by preferred term and 
system organ class. 
Treatment-emergent AEs by maximum severity, TEAEs  by relationship to study treatment, serious 
adverse events (SAE), TEAEs leading to death, and TEAEs leading to discontinuation of study treatment 
will be tabulated for each study treatment.  
All laboratory test results, vital signs measurement s, and ECG results will be summarized for each 
treatment group using descriptive statistics at each  visit for raw numbers and change from baseline. 
Test results from otoscopy, tympanometry, nasal a nd epipharynx endoscopy, UPSIT olfactory test, and 
audiology pure tone hearing test will be listed and summarized as appropriate. 
Safety Review Committee 
After all subjects in Cohort A have completed the Da y 14 visit, a SRC will review all the blinded safety 
data to determine whether the doses administer ed are safe and well tolerated and to make a 
recommendation to escalate to the next cohort (Cohort B) or not. 
Data Monitoring Committee: Yes 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 14 1.2 Schema 
Figure 1 Study Schema 
 
 
 

CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 15 1.3 Schedule of Activities 
Table 3 Schedule of Activities 
Study Period 
(with Visit Windows) Screening 
Period Confinement Perioda 
(In-Clinic) Study Exit 
 Days -28 
to -1 
(Screening)  
In-Clinic Day -1 
(Admission) Day 1  
(Enrollment) Day 4 
 Day 8 
 Day 14 
 Day 15 
 Day 21 
(+5 Day)  
In-Clinic EaTb 
Informed Consent/Authorization X         
Demographics X         
Inclusion/Exclusion X X        
Pregnancy Test (Urine)c X X      X X 
Follicle Stimulating Hormone Testd X         
Urine Drug Screene X X        
Viral Serologyf X         
Medical, Surgical, Ear History X         
Physical Examinationg X       X X 
Vital Signsh X X X X X X X X X 
12-Lead ECGi X  X   X  X X 
Ear History X         
Otoscopyj X X  X X X    
Tympanometry X X  X X X  Xo Xp 
Nasal and Epipharynx Endoscopyk X X   X X    
Clinical Laboratory Testsl X     X   X 
UPSIT Olfactory Testm X    X X  Xn X 
Audiology Pure Tone Hearing Test X     X  Xo Xp 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 16 Study Period 
(with Visit Windows) Screening 
Period Confinement Perioda 
(In-Clinic) Study Exit 
 Days -28 
to -1 
(Screening)  
In-Clinic Day -1 
(Admission) Day 1  
(Enrollment) Day 4 
 Day 8 
 Day 14 
 Day 15 
 Day 21 
(+5 Day)  
In-Clinic EaTb 
Admission   X        
Train Participant on Study Product 
Administrationq  X X       
Randomization  X        
Study Treatmentr   X X X X    
Concomitant Medications X X X X X X X X X 
Adverse Events X X X X X X X X X 
PK Sample Collection   Xr   Xs    
Device Experience Questionnaire – 
Subjectt       X  Xu 
Device Experience Questionnaire – 
Study Center Staff Administering the Treatment
t       X  Xu 
EaT = Early termination; ECG = Electrocardio gram; IP = Investigational Product; PK = ph armacokinetic; UPSIT = University of Pen nsylvania Smell Inventory 
Test. 
a Eligible healthy volunteers will be admitted to the study center  on Day -1 and be randomized on Day -1.  Subjects will remain  resident at the study center 
until after all the Day 15 assessments have been completed. 
b EaT: To be performed if the subject was treated but early discontinue from the study. c For all females, urine pregnancy test must be  negative to meet study enrollment criteria. 
d To be performed on postmenopausal women at Screening to confirm menopausal status (see Appendix 6 ). 
e Specific tests to be conducted are listed in Table 8 , Appendix 3 . 
f To be performed at Screening only (see Table 8 , Appendix 3 ). 
g Includes general appearance, overall status of the skin, head, neck, trunk, eyes, heart and lungs (eg, breathing sounds), abd omen, extremities, lymph nodes. 
Height and weight are recorded  only at the Screening visit. 
h Vital signs include blood pressure, respiratory rate, pulse rate, and body temperature. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 17 i A single 12-lead ECG will be collected for screening purposes . For subjects in Cohort A, a single 12-lead ECG will be collect ed on Day 1 prior to the first 
dose and on the study exit visit (Day 21). For subjects in Cohort B, triplicate ECGs will be collected on Day 1: 30 and 60 minu tes prior to the first dose, 
Day 14: 30 minutes prior to the last dose and 5, 20, 35, 50 minutes following the last dose on Day 14. In cases where ECG and P K sampling overlap, ECGs 
should be collected first, to en sure that PK samples are collected at the scheduled time point. 
j Otoscopy involves ear endoscopy, taking a picture of the tympanic membrane and assessing if there are any abnormal findings. k Nasal endoscopy will include a measurement of nasal cavity leng th (in mm) at the Screening visit only. For all other schedule d assessments, the nasal and 
epipharynx endoscopy assessment should be done prior to the first dose of the day. 
l Includes hematology, clinical chemistry, coagulation and urinalysis (see Table 8 , Appendix 3 ). 
m At Screening, a total UPSIT score of ≥35 (for females) and a total UPSIT score of ≥34 (for males) is required to  meet study enrollment criteria. 
n To be collected at the Day 21 study exit visit only if abnormal at the Day 14 visit. Abnormal is defined as UPSIT score <35 ( for females) and <34 (for males) 
(see Section 8.2.8 ). 
o Audiology pure tone hearing test if abnormal in either ear at Day 14 visit. Abnormal defined as >20 dB worsening from baselin e at Day 14 visit 
(Rosenfeld et al, 2004) .  Typanometry is performed along with the Audiology pure tone hear ing test so if the subject requires a hearing test at this v isit, 
tympanometry will also be performed. 
p Audiology pure tone hearing test and tympanometry not required if subjects drops out before Day 14, but if they drop out afte r Day 14 and had an abnormal 
test result at Day 14 visit, then every effort should be made to have the patient complete these assessments at the EaT visit. 
q Study subjects need to be trained on study treatment administration on Day -1 or on Day 1, prior to the first dose.   r Study treatment dosing recommendation: the first dose at 9:00 am, second dose at 16:00 pm and the third dose at 23:00 pm. s PK sample timing Cohort B only: Day 1: 30 and 60 minutes prior to the first dose, Day 14: 30 minutes prior to the last dose a nd 5, 20, 35, 50 minutes 
following the last dose on Day 14. The 5-minute PK sample should be collected within ±2 minutes of the scheduled time and the 2 0-minute PK sample should 
be collected within +5 minutes of the sche duled time. All other PK samples should be collected within ±5 minutes of the schedul ed time. 
t To be completed before discharge from the study center on the morning of Day 15 (See Appendix 7  for an example). 
u This assessment is needed only if subjects discontinue the study prior to completing the questionnaire on Day 15.  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 18 2.0 INTRODUCTION 
2.1 Study Rationale 
OP0201 metered dose inhaler (MDI) (referred herein simply as OP0201) is a novel, intranasal 
drug-device surfactant product bei ng developed by Novus Therapeu tics, Inc., for the treatment 
and prevention of otitis media (O M).  To date, there is no drug product that has been approved to 
treat or prevent OM.  
OP0201 is comprised of a 20:1 fixed combina tion of dipalmitoylphosphatidylcholine (DPPC; a 
phospholipid surfactant) and choles teryl palmitate (CP; a neutra l phospholipid spreading agent) 
suspended in propellant (HFA 134a).  There are no other ingredients (ie, no  excipients, no fillers) 
in the formulation other than th e active ingredients and the propellant.  None of these ingredients 
contain any animal or human derivatives.  Both DPPC and CP are highly endogenous surfactants 
in humans, including the Eustachian tube ( ET), nasopharynx, and resp iratory system.   
The drug product will be delivered as a local tr eatment through each nostril using a metered dose 
inhalation device.  It will be sp rayed directly backwards into each  nostril by way of the anterior 
nostrils (not upwards towards the osteomeatal op ening to the maxillary and ethmoid sinuses as 
other common intranasal products) to wards the lateral wall of the nasal cavity so that the usual 
nasal mucociliary clearance pathway can facil itate delivery of the drug to the ET.   
This Phase 1 safety study is desi gned to evaluate the safety and tolerability of da ily intranasal 
OP0201 use for 14 consecutive days in 30 healthy adults.  The study will be randomized, double-blind, placebo-controlled, parallel-group, a nd includes a dose-escalation cohort design 
with evaluation of 30 mg per day (Cohort A)  and 60 mg per day (Cohort B) of OP0201.   
For more information about OP0201, please refer to the most recent Investigator’s Brochure 
(IB). 
2.2 Background 
The ET is a compliant liquid-lined tube between  the middle ear (ME) and the nasopharynx.  The 
ET serves 3 major physiologic func tions: 1) ventilation of the ME to maintain ambient air 
pressure, 2) clearance of fl uid from the ME to nasopharynx, and 3) protection of the ME 
(Chandrasekhar and Mautone, 2004; Siebert and Danner 2006 ).  In children, ET dysfunction 
resulting in inflammation of the ME, referred to as OM, is often triggered by a vira l infection of 
the upper respiratory system ( Chonmaitree et al, 2008; Thomas et  al, 2014; Schilder et al, 2016 ).  
Furthermore, the ET of infants and young child ren are short, floppy, hor izontal and function 
poorly, which makes ME flui d flow more challenging ( Rosa Olivares et al , 2015; Rovers et al, 
2004 ).  A viral infection increases mucus production as well as alters the properties of mucus in 
the nasopharyngeal region, resulting in dimin ished normal mucociliary clearance by mucosal 
cells of the ET and nasopharynx and creating infl ammation in the area.  This causes dysfunction 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 19 of the ET leading to negative ME.  The presence of viruses and/or bacteria in the ME results in 
inflammation and build-up of mucus or liquid behind the tympanic membrane (ie, OM).  
Common forms of OM are acute o titis media (AOM) and otitis media with effusion (OME).  
Otitis media with effusion is a build-up of mucu s/liquid behind the tympanic membrane without 
symptoms of an ear infection.  Often, there ar e no symptoms of OME;  or there are subtle 
findings (eg, ear rubbing,  clumsiness, conductive hear ing loss, and disturbed sleep).  In contrast, 
AOM often occurs when bacteria or viruses get trapped in the ME  and cause fever, ear pain and 
active (acute) inflammation.  Both AOM and OME are the result of a dysfunctional ET. 
Both DPPC and CP are established endogenous  components in human nasal passages and ET 
and are present on the liquid surface of the nasa l passage and ET mucosal lining, and the entire 
respiratory system. Among phospholipid compou nds, DPPC is the most hydrophobic and surface 
active ( Notter, 2000; Taeusch et al., 2002 ).  The hydrophobic nature of DPPC causes it to spread 
very slowly over an aqueous surface.  However, in the presence of a spreading agent (ie, CP), 
phospholipids easily “spread” along a surface pressure gradient of mucosal lined lumens 
(Colacicco and Basu, 1977; Notter, 2000 ).  Together these 2 active ingredients effectively absorb 
to the mucosal air-liquid interface and reduce th e interfacial surface tension of the ET, which 
reduces passive opening pressure required to open the ET.  In other words, DPPC + CP promotes 
‘de-sticking’ and restoration of physiologic activ ity of the ET.  Thus, the 3 major ET physiologic 
functions (clearance of fluid from the ME to nasopharynx, ventilation of the ME to maintain 
ambient air pressure, and protection of the ME) are restored.  In turn, it is hypothesized that acute 
symptoms of OM will be relieved by providing a physiologic opening to the closed ME space, and, with repeat usage, future OM episodes will be  prevented.  The surfact ant is delivered locally 
to the nasopharyngeal tissue via the nostrils to re duce the local surface tens ion and pressure that 
is preventing the ET from func tioning normally.  By restor ing ET functionality, OPO201 
facilitates normal ventilation of the ME, which in  turn corrects the negative ME pressure that 
causes otalgia (ear pain) in patients with AOM.  Restoring ET function fa cilitates ME drainage, 
which in turn may resolve hearing difficulties in  patients with OME.  In patients at risk of 
developing OM, delivering the su rfactant to the nasopharyngea l tissue via the nostrils may 
prevent ET dysfunction and in turn  prevent AOM and/or OME.   
2.3 Benefit/Risk Assessment 
As this study is being conducted in  healthy human subjects, a health  benefit to the subject is not 
expected. 
OP0201 has not yet been evaluated in humans in controlled clini cal studies.  T hus, information 
regarding expected adverse even ts (AEs) from controll ed clinical studies is unknown.  However, 
a limited amount of data from 9 hu man cases exposed to 1 or more  doses of other formulations 
of the investigational drug product (200:1 and 16:1 ratio) is available (see Section 5.2.1 of the IB 
for further information). 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 20 Surfactants, such as DPPC and CP, are component s in several pharmaceuti cal products that have 
received approval by health authorities, including United States (US) Food and Drug 
Administration (FDA) and many European Union (EU) countries, (eg, Alveofact®, Curosurf®, 
Infasurf®, and Survanta®) as intratracheal treatment of premat ure infants with respiratory distress 
syndrome (RDS).  The propellant excipient, HFA- 134a, is used in approved metered dose oral 
inhalers (eg, Proventil HFA® [albuterol], Aerospan® [flunisolide]) and intr anasal inhalers (eg, 
QNASL™ [beclomethasone]) containing active pharm aceutical agents for the management of 
asthma and chronic obstructive pulmonary diseas e.  The device used to deliver OP0201 to the 
nostrils is similar to devices utilized in the delivery of other appr oved inhaled metered dose 
products. 
The Sponsor will immediately notify the Principa l Investigator if any additional safety or 
toxicology information become s available dur ing the study. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 21 3.0 OBJECTIVES AND ENDPOINTS 
Table 4 Study Objectives and Endpoints 
Objectives Endpoints 
Primary  
 To evaluate the safety and tolerability of OP0201 
30 mg per day (given as 2 sprays per nostril 3 times a day [TID] for 14 consecutive days) and 
OP0201 60 mg per day (given as 4 sprays per 
nostril TID for 14 consecutive days) compared to 
0 mg placebo (HFA-134a on ly) administered in a 
similar parallel-group fashion TID for 14 consecutive days in healthy adult volunteers.  Adverse events, otoscopy, tympanometry, nasal 
and epipharynx endoscopy, University of Pennsylvania Smell Inventory Test (UPSIT) 
olfactory test, audiology pure tone hearing test, 
triplicate 12-lead electro cardiogram, physical 
examination, vital signs, and clinical laboratory 
tests.   
 
Secondary/Exploratory  
 To evaluate if any systemic exposure of 
dipalmitoylphosphatidylcholine (DPPC) can be 
detected in serum at levels higher than endogenous DPPC levels in serum in up to 15 healthy adult 
volunteers who will be evaluated in the Cohort B 
dose (OP0210 60 mg per day) versus placebo. 
 To evaluate if any systemic exposure of 
cholesteryl palmitate (CP) can be detected in 
serum at levels higher than endogenous CP levels in serum in up to 15 healthy adult volunteers who 
will be evaluated in the Cohort B dose (OP0210 60 
mg per day) versus placebo.  Maximum baseline adjusted serum concentration 
(C
max) of DPPC on Day 14. 
 Time to maximum concentration (t max) of DPPC 
on Day 14. 
 Maximum baseline adjusted serum concentration 
(Cmax) of CP on Day 14. 
 Time to maximum concentration (t max) of CP on 
Day 14. 
 Additional parameters may be calculated, if 
appropriate. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 22 4.0 STUDY DESIGN 
4.1 Overall Design 
This is a randomized, double-blind, placebo-c ontrolled, parallel-group, dose-escalation study in 
healthy volunteers to evaluate th e safety and tolerability of OP0201 administered intranasally 
3 times a day (TID) using a MDI compared to a matching placebo (HFA-134a minus active 
ingredients) administered intranasally TID using a MDI for 14 consecutive days (see Figure 1  for 
the study schematic).  The plan is to enroll up to  30 subjects at 1 study ce nter in the US.  Two 
dose cohorts are planned (Cohort A and Cohort B;  N=15 per cohort, see Cohort Dosing below, 
Table 5 ).  Within each cohort, subj ects will be randomized in a 4:1 ratio to receive either 
OP0201 or placebo.  After all subjects in Cohort A have completed the Day 14 visit, a Safety 
Review Committee (SRC) will review all the blinde d safety data to determine whether the doses 
administered are safe and well tolerated.  The SRC will make a recommendation to escalate to 
the next cohort (Cohort B) or not. 
Table 5 Dose Cohorts and Dose Regimen 
Cohort Dose Regimen Cohort Dose Allocation Total 
Subjects in 
Each 
Cohort Total 
Subjects Per 
Dose Group 
Per Day Total Dose 
(mg) Cumulative Total Dose 
(mg) 
A 2 sprays per 
nostril TID x 14 
days 
 OP0201 (30 mg)a 
 
Placebo (0 mg) 
 OP0201 (420 mg) a 
 
Placebo (0 mg) 
 15  
N=12 (OP0201) 
N=3 
(Placebo)  
B 4 sprays per 
nostril TID x 14 days 
 OP0201 (60 mg)
 a 
 Placebo (0 mg) 
 OP0201 (840 mg)
 a 
 Placebo (0 mg) 
 15  
N=12 
(OP0201) 
N=3 
(Placebo) 
a 2.5 mg per spray 
N = number of subjects; TID = 3 times a day 
 
Potential subjects will be screened for eligibilit y during a screening period (Days -28 to -1).  
Eligible healthy volunteers will be admitted to  the study center on Day -1 and be randomized on 
Day -1.  Subjects will remain re sident at the study center until after all the Day 15 assessments 
have been completed (see Table 3  for the Schedule of Assessment s [SoA]), with a study exit visit 
at Day 21. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 23 Study treatment will be administere d to the subjects by study center staff TID for 14 days while 
resident at the study center.   
The estimated duration of particip ation in the study for each subject is up to 54 days: Screening 
(Days -28 to -1), treatment (Day 1), 16-day resi dency (Day -1 to Day 15 with safety assessments 
at Days 4, 8, 14 and 15), study exit (Day 21 [+ 5 days]).  No efficacy assessments will be 
performed for this study. 
4.2 Scientific Rationale for Study Design 
This study is designed to evaluate  the safety and tolerability of  OP0201 versus placebo in healthy 
volunteers using a well-designed, scientif ic method for comparing treatments.  
The study design is that of a well -controlled clinical study that includes elements necessary for a 
valid evaluation of safety and tolerability of rep eat OP0201 doses for 14 days.  The study is 
randomized, and treatment is masked for the Investigator, study center personnel, and the 
subjects to minimize bias.  A parallel-group de sign eliminates possible confounding effects that 
are inherent in other stud y designs (eg, cross over).   
The placebo (HFA-134a minus active ingredients) was selected to evaluate the comparative 
safety profile of OP0201 versus a non-drug cont aining control arm.  HFA-134a was chosen as 
the placebo control sinc e it is the propellant used in the OP0201 formulation.  HFA-134a is used 
as a propellant in other marketed  nasal products and has a good safe ty and tolerability profile in 
patients suffering from perennial allergic rhinitis ( Weber et al, 2006 ).   
The current study is designed to show that OP0201 is safe and well tolera ted compared to the 
placebo ( FDA Drug Study Designs - Information Sheet ). 
4.3 Justification for Dose 
The US FDA has agreed that animal toxicology studies with OP0201 are not needed to proceed 
with evaluating this treatment in humans, sin ce the active ingredients are present in other 
marketed products and the active ingredients ar e highly endogenous to the human respiratory 
tract.  The composition of OP0201 is designed to  maximize the lowering of the mucosal surface 
tension.  Safety and proof of concept results from animal pharmacology st udies are considered 
supportive of the formulation inte nded for human use.  Across se veral nonclinical pharmacology 
studies, the beneficial effects of  OP0201 were consistently better than those of no treatment and 
treatment with placebo alone (H FA-134a minus active ingredients)  (see IB, Section 4, for more 
details).  A multiple day dose of  20 mg twice daily was given to  chinchillas for 10 days.  The 
total exposure was calculated at 400 mg over 10 days; approximately 800 to 1100 mg/kg for a 
chinchilla weighing 0.35 to 0.5 kg ( Chandrasekhar and Mautone, 2004 ).  No AEs were observed 
in any of the animal studies.  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 24 The clinical safety and tolerability of  OP0201 (DPPC:CP 20:1 [w eight/weight] (w/w), 
manufactured by Novus Therapeutics, Inc.) for hu man use is further gui ded by a limited amount 
of data from 9 human cases exposed to 1 or more doses of other formulations of the 
investigational drug product (200 :1 w/w and 16:1 w/w).  A total of 8 cases were exposed to 
DPPC:CP 16:1 w/w in HFA-134a with each 0.1 mL  spray delivering 2.5 mg active ingredient.  
One case exposed to DPPC:CP 200:1 w/w in HFA- 134a, with each 0.1 mL spray delivering 5 mg 
of active ingredient (see IB, Section 5.2.1).   
This Phase 1 safety study is designed to ev aluate the safety and tolerability of OP0201 in 
30 healthy volunteers.  The dosing regimen for each of the 2 dose cohorts to be evaluated in this 
study are defined in Table 5 .  A TID dosing exceeds the anticipated once daily or maximum 
twice daily dosing interval that may be evaluated in  patients in future studies.  Because of the 
endogenous nature of the active ingr edients, pharmacokinetic (PK) profiles cannot be obtained to 
guide on dose or dosing interval.  Fu rthermore, the treatment is anti cipated to have a local effect 
on the ET, and thus systemic plasma levels woul dn’t necessarily have relevance.  The maximum 
number of sprays of 4 per nostril to be evaluated in this Phase 1 study also exceed the anticipated 
practical maximum number of sprays  of 2 per nostril that will be ev aluated in patients in future 
studies.  The dose, number of sprays, and dosing interval for this Phase 1 study were chosen 
because they are expected to exce ed the total daily dose for dosing schema that will be tested in 
patients in future studies, and thus establish a high safety threshold.  
The surfactant active ingredients of OP0201 ar e endogenous to human nasal and respiratory 
mucosal surfaces.  Additionally, surfactants have been approved for topical administration via the trachea to infants with RDS with a long histor y of safety and tolera bility at much higher 
exposure levels on a mg/kg basis than proposed he rein (see IB, Section 4.1.5, Table 5).  Thus, in 
this study daily repeat maximum doses of 20 mg TID for 14 days are to provide an estimated 
total exposure of 840 mg over 14 days; approx imately 12 mg/kg for a human weighing 70 kg. 
Rationale for Route of Administration 
The target end organ for the study treatment is the ET, which exits the ME and resides in the 
nasopharynx.  In adults, the nasal passage exte nds about 10 to 14 cm from the nostrils to the 
nasopharynx ( Reznik, 1990 ).  Access to the ET is via the nostril.  Because of the physical 
location of the ET in the nasopharynx, the a ngle of the delivery of  the investigational 
product (IP) in the nostril is in a horizontal direction towards the back of the nose, not vertical 
towards the sinus cavities (not ‘up’  into the nose) as for other na sal inhaled products.  The IP is 
delivered using a MDI; thus there is no need for the user to sniff or breathe in a certain way for 
the IP to reach the ET.   
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 25 4.4 End of Study Definition 
A subject is considered to have  completed the study if he/she has completed all phases of the 
study including the last visit. 
The end of the study is defined as  the date of the last visit of  the last subject in the study. 
4.5 Dose-Escalation Criteria 
After all subjects in Cohort A have completed th e Day 14 visit, a SRC will review all the blinded 
safety data to determine whether the doses admini stered are safe and well tolerated and to make a 
recommendation to escalate to th e next cohort (Cohort B) or not. 
4.6 Study Stopping Criteria 
4.6.1 Stopping Criteria for Individual Subjects 
Study treatment for any individual  subject will be stopped if the subject experiences a serious 
adverse event (SAE) or a clinically significant possibly drug-related related AE, which in the 
opinion of the study physician, Pr incipal Investigator, or Spon sor’s medical representative, 
warrants discontinuation of the study for that subject’s wellbeing.  See Section 7.1 for general 
discontinuation procedures. 
Any female subject who becomes pregnant while participating in the study will be withdrawn 
from the study. 
4.6.2 Criteria for Stopping Dose-Escalation 
Dose-escalation will be stopped if any of the study stopping rules are met. 
4.6.3 Criteria for Stopping the Study 
If 1 or more subjects experien ce drug-related SAEs or 2 or more subjects experience any 
drug-related severe AEs, the study will be stopped. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 26 If any of the following scenarios occur with a reas onable possibility of a causal relationship with 
the study treatment, the study will be stopped: 
 ≥1 subject experiences SAEs considered to have  a reasonable possibili ty of relationship to 
the study treatment. 
 ≥2 subjects experience non-tolerable AEs that ar e considered to have a reasonable possibility 
of relationship to the study treatment. 
 ≥1 subject receiving study treatment fulfills Hy ’s Law defined as alanine aminotransferase 
(ALT) >3 × the upper limit of normal (ULN) and bilirubin >2 × ULN in the absence of 
significant increase in alkaline phosphatase (A LP) and in the absence of an alternative 
diagnosis that explains the increase in tota l bilirubin, to be assessed from the first 
administration of study treatment up to and including follow-up. 
 ≥2 subjects who receive study tr eatment have >2 ULN of eith er ALT, bilirubin, or ALP. 
 ≥2 subjects who receive study treatment have a QTc prolongation defined as QTcF >500 ms, 
or an increase of QTcF >60 ms above baseli ne on the 12-lead electrocardiogram (ECG), 
confirmed (persistent for >5 min utes) on repeated 12-lead ECGs. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 27 5.0 STUDY POPULATION 
Prospective approval of protocol deviations to recruitment and en rollment criteria, also known as 
protocol waivers or exem ptions, are not permitted. 
Healthy volunteers are those who ar e otherwise healthy and who m eet the eligibility criteria 
below. 
5.1 Inclusion Criteria 
Healthy volunteers are eligib le to be included in the study only if all of the fo llowing criteria 
apply:  
1. Subject has signed an informed  consent form (ICF) before any study-specific procedures 
are performed. 
2. Male or female healthy volunt eers aged 18 to 50 years at the time of signed informed 
consent.   
3. Able and willing to follow study instructi ons (including compliance with daily study 
treatment administration) and li kely to complete all require d study visits as assessed by 
the Investigator’s judgement.  
4. Body mass index of 18 to 30 kg/m2 (inclusive) and a minimu m body weight of 50 kg at 
Screening. 
5. Female subjects must agree to use an acceptable method of contraception (see Appendix 6  
for pregnancy considerations a nd contraceptive requirements). 
6. Female subjects who are of childbearing poten tial must have a negative urine pregnancy 
test result at Screening and Da y -1 prior to randomization. 
7. Male subjects must agree to use contraception as detailed in Appendix 6  of this protocol 
during the treatment period. 
8. Subjects must agree to refra in from immersing their head fully under water (eg, 
swimming, diving) from the time of signed inform ed consent until after the study exit visit 
(Day 21). 
9. Physiologic tympanogram classified as Type A (normal) by the Investigator or designee. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 28 5.2 Exclusion Criteria 
Subjects are excluded from the study if any of the following criteria apply: 
1. History or presence of signi ficant medical condition or a cl inically signifi cant abnormal 
finding, as determined by the Investigator.  This includes study sc reening results from: 
 Medical history 
 Physical examination 
 ENT examination (ear history, otos copy, tympanogram, nose and epipharynx 
endoscopy) 
 University of Pennsylvania Smell Inve ntory Test (UPSIT)  olfactory test 
 Audiology pure tone hearing test 
 ECG  
 Vital signs measurements 
 Clinical laboratory tests 
2. Presence of a clinically significant abnormal olfa ctory test finding at Screening defined as 
a total UPSIT score <35 (for fe males) and <34 (for males). 
3. Current diagnosis of Sleep Apnea.  
4. Clinically significant ear disorder/disease curre ntly or within 6 week s prior to Screening. 
5. History of tympanostomy tubes in one or bot h ears within 1 year prior to Screening. 
6. Upper respiratory tract infect ion or pharyngitis currently or  within 6 weeks prior to 
Screening. 
7. Allergy or sinus conditions (eg, sinusitis, non -specific nasal infla mmation) currently or 
within 6 weeks prior to Screening. 
8. Clinically relevant blockage of one or both nasal passages, in the Investigator’s opinion. 
9. Gastroesophageal reflux disease currently or within 6 weeks prior to Screening. 
10. Smoker (eg, cigarettes, vapor) or tobacco or ni cotine use within the last 48 weeks prior to 
Screening and positive urine cotinine test re sults at Screening or Day -1 prior to 
randomization.  
11. Females with positive urine pregnancy results at Screening or Day -1 prior to 
randomization.  
12. Females who are nursing or planni ng a pregnancy during the study.  
13. Females of childbearing poten tial who are not willing to use an acceptable method of 
contraception during the study (see Appendix 6 ). 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 29 14. Symptomatic herpes zoster within 12 weeks prior to Screening. 
15. Lymphoma, leukemia or any mali gnancy within the past 5 year s except for basal cell or 
squamous epithelial carcinomas of the skin th at have been resected with no evidence of 
metastatic disease for 3 years. 
16. Breast cancer within the past 10 years. 
17. Live vaccine within 30 days prior to Screen ing, or plans to receive  such vaccines during 
the study. 
18. Evidence of craniofacial anomalies (eg, cleft palate, Down’s Syndrome). 
19. Disorders with decrease mucoci liary clearance or higher vi scosity of the mucous (eg, 
cystic fibrosis, primary ciliary dys kinesia, Karfagen er’s syndrome). 
20. Use of any medication (either to pically or systemic ally) for a condition related to the ear 
or nose currently or within 12 weeks prior to Screening. 
21. Use of medications with known vasoconstric tive properties (eg, local anesthetics, 
decongestants) currently  or within 2 weeks prior to Screening. 
22. Use of medications with known anti-cholin ergic side effects (eg, antihistamines, 
antiemetics, muscle relaxants, antidepressant s) currently or within 6 weeks prior to 
Screening. 
23. Within 7 days prior to the fi rst study treatment administra tion, use of any prescription 
drug (except oral contraceptive), nicotine- containing product (including nicotine patch), 
over-the-counter drug, herbal supplement, vitamin, or dietary supplement with the 
exception for occasional use of aceta minophen not exceeding 3 grams per day. 
24. Regular alcohol consumption w ithin 24 weeks prior to Screen ing defined as an average 
weekly intake of >21 units for males and >14 uni ts for females; 1 unit is equivalent to 8 g 
of alcohol (a half pint [approximately 240 mL ] of beer, 1 glass [a pproximately 125 mL] of 
wine or 1 measure [approxima tely 25 mL] of spirit). 
25. History of drug abuse or positive drug screeni ng test at Screening or Day -1 prior to 
randomization (see Table 8 , Appendix 3 ). 
26. Known allergy or sensitivity to the st udy treatment or any of its components. 
27. Exposure to 3 or more new chemical entitie s within 12 months pr ior to Screening. 
28. Investigator and study center pe rsonnel directly affiliated with this study and/or their 
immediate families (defined as spouse, significant-other, pare nt, child or sibling, whether 
adopted or biologic).  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 30 29. Persons employed by the S ponsor or Investigator. 
30. Persons held in an instituti on by legal or official order. 
31. Concurrent enrollment in an investigational drug or device study other than the research 
pertaining to OP0201, or participation in such  a study within 30 days of Screening. 
32. Subject has a condition or is in  a situation which, in the Inve stigator's opinion, may put the 
subject at significant risk, ma y confound the study results, or  may interfere significantly 
with the subject's participation in the study. 
5.3 Lifestyle Considerations 
Please see Section 6.5 for medications that are prohibited during this study. 
Subjects must refrain from imme rsing their head fully under water (eg, swimming, diving) from 
the time of signed informed consent until after the final study exit visit (Day 21). 
5.3.1 Meals and Dietary Restrictions 
1. Subjects should abstain from consuming grapefru it, grapefruit juice, cranberry juice, and 
other cranberry containing produc ts or any products made with  Seville oranges (eg, orange 
marmalade) from 14 days before admission to the study center until after the final study exit 
visit (Day 21). 
5.3.2 Caffeine and Alcohol 
1. Subjects will abstain from caffe ine or xanthine-containing products  for at least 48 hours prior 
to admission to the study center and for the duration of the stay in the study center. 
2. Subjects will abstain from alcohol from Scr eening until after the final study exit visit 
(Day 21).  
5.3.3 Activity 
1. All subjects must comply with the c ontraception requirements as noted in Appendix 6 . 
2. Subjects should refrain from strenuous exer cise for 24 hours before Screening, before 
admission and for the duration of the study. 
3. Subjects will be advised not to  donate blood or plasma for at least 3 months after the last 
dose administration. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 31 5.4 Screen Failures 
Screen failures are defined as subjects who consen t to participate in the clinical study but are not 
subsequently randomly assigned to  study treatment.  A minimal set of  screen failur e information 
is required to ensure transparen t reporting of screen failure s ubjects to meet the Consolidated 
Standards of Reporting Trials publishing requirem ents and to respond to queries from regulatory 
authorities.  Minimal information includes de mography (eg, age, gender, race), reasons for 
screen failure (eg, note which eligibility criteria was not met), and any SAE.   
Individuals who do not meet  the criteria for particip ation in this study (scr een failure) may not be 
rescreened. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 32 6.0 STUDY TREATMENT 
Study treatment is defined as any investigationa l treatment(s), marketed  product(s), placebo, or 
medical device(s) intended to be administered to a subject a ccording to the study protocol. 
The study treatment is to be used in accordance with the protocol for h ealthy volunteers who are 
under the direct supervision of a qualified Investigator. 
6.1 Study Treatment(s) Administered 
The following study treatments wi ll be used in this study.  
Study Treatment #1:  OP0201 
OP0201 is an intranasal aerosol, a dosage form  recognized by the US Pharmacopeia, that is 
comprised of 2 active ingredients, DPPC and CP , in approximately 20:1 (w/w) ratio, suspended 
in an inactive ingredient, the synthetic ch lorofluorocarbon-free pr opellant HFA 134a.  All 
OP0201 ingredients are synthetic;  none of these ingredients contain any animal or human 
derivatives.  OP0201 is supplied in  mechanical packing parts that  includes a pressurized canister 
with a securely attached mete ring valve where the drug product is  contained, an actuator into 
which the canister is seated and the valve conne cts with device body, and a tip to deliver the drug 
to the nostrils. 
OP0201 is manufactured using Good Manufacturing Processes (GMP) with development phase 
appropriate compliance with global Health Authority guidelines (eg, US FDA Guidance for 
Industry: Nasal Spray and Inhalation Soluti on, Suspension and Spray Drug Products, July 2002 ) 
by xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx.  The OP0201 canisters 
are filled to deliver 100 actuati ons (sprays) per canister.  Ea ch MDI spray of OP0201 delivers 0.1 
mL of HFA-134a containing a total of 2.5 mg of  the active pharmaceutical ingredients as dry 
powder suspended in the HFA-134a. 
See the IB for further details regarding OP0201. 
Study Treatment #2:  Placebo 
The placebo is comprised of the same synthe tic chlorofluorocarbon-free propellant, HFA-134a, 
an inactive ingredient as used  in the study treatment #1 desc ribed above.  The placebo is 
manufactured using GMP with development phase appropriate compliance with global Health 
Authority guidelines (eg, US FDA Guidance for Industry: Nasa l Spray and Inhalation Solution, 
Suspension and Spray Drug Products, July 2002 ) by xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx.  
The placebo canisters are filled to deliver 100 actua tions (sprays) per canister.  Each 0.1 mL 
MDI spray of placebo delivers 0.1 mL of HFA-134a. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 33 For each dose, the subject will have administered to them by the study center staff, 2 (Cohort A) 
or 4 (Cohort B) consecutive sprays first to the left nostril and then  to the right nos tril for a total 
of 4 (Cohort A) or 8 (Cohort B) sprays (see St udy Manual for Study Treatme nt Instructions for 
Use).  The dose will be repeated 3 times a da y for a total of 14 days (42 doses).   
The study treatment will be administered every 7 hours: a morning dose at  9:00 am, an afternoon 
dose at 16:00 pm and an evening dose at 23:00 pm.  The Investigator or qualified designee will record each dose by noting the time  and number of total sprays ad ministered successfully in a 
dosing log. 
6.2 Preparation/Handling/Storage/Accountability 
1. The Investigator or designee must confirm a ppropriate temperature conditions have been 
maintained during transit for a ll study treatment received and a ny discrepancies are reported 
and resolved before us e of the study treatment. 
2. Only subjects enrolled in the study may r eceive study treatment a nd only authorized study 
center staff may supply or admini ster study treatment. All study tr eatments must be stored in 
a secure, environmentally cont rolled, and monitored (manua l or automated) area in 
accordance with the labeled storage conditions with access limited to the Investigator and 
authorized study center staff. 
3. The Investigator, institution, or the head of the medical inst itution (where a pplicable) is 
responsible for study treatment accountability, re conciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records). 
The Investigator, a member of th e study center staff, or  a pharmacist must ma intain an adequate 
record of the receipt and di stribution of all study medicati on using the Drug Accountability 
Form. These forms must be availa ble for inspection at any time. 
6.3 Measures to Minimize Bias: Randomization and Blinding 
6.3.1 Study Treatment Kit 
Each study treatment kit will be labeled with a kit number and contain a predetermined number 
of units.  For this study, a unit is defined as 1 canister of study tr eatment.  Each kit will include 
the necessary amounts of units of study treatme nt; according to the study treatment cohort and 
dose level.  Further details will be  provided in the Laboratory Manual. 
On Day 1 subjects will be assigned a unique  number (randomizati on number) in ascending 
numerical order.  The randomiza tion number encodes the subject’s assignment to 1 of the 2 study 
treatments of the study, according to the randomiza tion schedule generated prior to the study by 
the Statistics Department at the Sponsor or de signee.  Each subject will be assigned blinded 
study treatment, labeled with his/her unique rand omization number, that will be used throughout 
the study. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 34 Within each dose cohort, subjects will be rando mly assigned in a 4:1 ratio to receive OP0201 or 
placebo.  The randomization scheme will be  prepared by the Sponsor’s designee. 
6.3.2 Blinding 
Study treatment will be provided in identically appearing canisters and kits to ma intain masking 
of the study. 
6.3.3 Procedures for Unblinding Study Treatment 
A sealed envelope that contains  the study treatment a ssignment for each s ubject will be provided 
to the Investigator.  The sealed envelope will be retained by the Investigator (or representative) 
in a secured area.  In case of an emergency, the Investigator has the sole re sponsibility for 
determining if unblinding of a s ubject’s treatment assignment is wa rranted.  Subject safety must 
always be the first consideration in making such a deter mination.  If the Inves tigator decides that 
unblinding is warranted, the Inves tigator should make every effo rt to contact the Sponsor and 
Medical Monitor prior to unbli nding a subject’s treatment assi gnment unless this could delay 
emergency treatment of the subject.  If a subject’s treatment assi gnment is unblinded, the 
Sponsor and Medical Monitor must be notified within 24 hours after breaking the blind.  Once 
the study is complete, all envelope s (sealed and opened) must be inventoried and returned to the 
Sponsor. 
6.4 Study Treatment Compliance 
The prescribed dosage, timing, and mode of ad ministration may not be changed, except as 
defined in Section 6.6.   
Only subjects enrolled in the study may receiv e study treatment and only authorized study center 
staff may adminis ter the study treatment to the subject.   
The Investigator or qualified designee will reco rd each dose by noting the time and number of 
total sprays administered su ccessfully in a dosing log. 
6.4.1 Treatment Strategy for Emergencies 
The clinical study center is a larg e clinical pharmacology Inpatient  Unit that has 24-hour staffing 
and security coverage 7 days a week and is loca ted within 5 miles of 3 local hospitals, one of 
which is a trauma center.  Hi ghly trained Paramedic/Emergency Medical Technicians (EMT) are 
available in the study center on a 24-hour basis and are trained to deal specifically with 
life-threatening AEs and medical emergencies.  All EMTs are Advance Cardiovascular Life 
Support certified, and all study center staff are Ca rdiopulmonary Resuscit ation certified.  All 
equipment necessary for resuscitative care is available in th e study center.  The study center is 
equipped with 24/7 video surveillance/controll ed access throughout the f acility, strategically 
located panic buttons, 48-cha nnel cardiac telemetry and co ntinuous pulse oximetry and 
2 emergency crash carts. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 35 6.4.2 Warnings and Precautions 
As this is the first administration of OP0201 to  healthy human volunteers , all effects cannot be 
reliably predicted.  The preclinical data suggest  an acceptable safety profile.  In addition, the 
active pharmaceutical ingredients in the study treat ment are endogenous to humans.  Facilities 
and staff for resuscitation and the treatment of other medical emergencies will be provided. 
6.5 Concomitant Therapy 
Any medication or vaccine (including over-the-c ounter or prescription medicines, vitamins, 
and/or herbal supplements) that the subject is receiving at the time of enrollment (within 7 days 
before the time of enrollment) or receives dur ing the study must be recorded on the electronic 
case report form (eCRF) along with: 
 Reason for use. 
 Dates of administration incl uding start and end dates. 
 Dosage information in cluding dose and frequency. 
The Medical Monitor should be c ontacted if there are any questi ons regarding concomitant or 
prior therapy. 
Subjects must abstain from ta king prescription or nonprescripti on drugs (including vitamins and 
dietary or herbal supplements) w ithin 7 days or 5 half-lives (whi chever is longer) before the start 
of study treatment until completion of the study exit visit (Day 21).  In th e case of medications 
(either topically or syst emically) for a condition re lated to ear or nose, subjects must abstain from 
taking these within 12 weeks befo re the start of study treatment , or 2 weeks in the case of 
medications with known vasoconstrictive propertie s (eg, local anesthetics,  decongestants), or 
6 weeks in the case of medications with known an ti-cholinergic side effe cts (eg, antihistamines, 
antiemetics, muscle relaxants, antidepressants).  An exception is that women of childbearing 
potential (WOCBP) may take protocol de fined acceptable oral contraceptives.  
Acetaminophen, at doses of ≤ 3 grams/day, is permitted for us e any time during the study.  Other 
concomitant medication may be considered on a case-by-case basis by the Investigator in 
consultation with the Medical Monitor (if required). 
6.6 Dose Modification 
Dose modifications are no t planned in this study. 
6.7 Treatment After the End of the Study 
The Sponsor will not provide any additional care  to subjects after they leave the study. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 36 7.0 DISCONTINUATION OF STUDY TREATMENT AND 
SUBJECT DISCONTINUATION/WITHDRAWAL  
If a clinically significant finding is identified, the Investigator  or qualified designee will 
determine if the subject should c ontinue with the study treatment and if any change in subject 
management is needed, and/or if  they should remain in the study.  Any new clinically relevant 
finding should be reported as an AE. 
7.1 Discontinuation of Study Treatment  
Subjects should not receive furt her study treatment if one or mo re of the following criteria are 
met.  It is not necessary to exit the particip ant from the study as long as they do not receive 
further study treatment.  The I nvestigator may use their disc retion in deciding whether to 
discontinue the particip ant from the study.  If the subject is discontinued from the study early, 
see SoA (Section 1.3) for data to be collected at the ti me of study discontinuation.  The reason 
that the study treatment is stopped shoul d be documented on the appropriate eCRF. 
7.2 Subject Discontinuation/Wit hdrawal from the Study 
Randomized subjects who meet any of the follo wing criteria should not receive further study 
treatment and should be exited from the study.  See SoA (Section 1.3) for data to be collected at 
the time of study exit.   
 Investigator or Sponsor (or its  designee) decides to discontin ue subjects from the study for 
safety, behavioral, compliance,  or administrative reasons. 
 Investigator or Sponsor (or its  designee) decides to discontin ue subjects from the study who 
are inadvertently enrolled into  the study despite signi ficant deviation from protocol-specified 
inclusion/exclusion criteria. 
 Subject indicates that they no longer want to participate in the study.  If the subject 
withdraws consent for disclosure  of future information, the Sp onsor may retain and continue 
to use any data collected before  such a withdrawal of consen t.  If a subject withdraws from 
the study, he/she may request destruction of any samples taken and not tested, and the 
Investigator must document this in the study cente r study records. 
Notification of early subject w ithdrawal from the study and the r eason for discontin uation will be 
clearly documented and noted in the eCRF.  If the subject exit s the study prior to the Day 21 
study exit visit, all of the Day 21 final measur ements should be performed and recorded on the 
appropriate eCRF. 
Subjects who are discontinued from the study may be replaced based on the Sponsor’s 
discretion. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 37 7.3 Lost to Follow-up 
A subject will be considered lost to follow-up if he or she repeated ly fails to return for scheduled 
visits and is unable to be c ontacted by the study center.  
The following actions must be taken if a subject fa ils to return to the c linic for a required study 
visit: 
 The study center must attempt to  contact the subject and resc hedule the missed visit as soon 
as possible and counsel the subject on the importance of maintain ing the assigned visit 
schedule and ascertain whether or not the subjec t wishes to and/or s hould continue in the 
study. 
 Before a subject is deemed lost  to follow-up, the Investigator  or designee must make every 
effort to regain contact with the subject (where possible, 3 te lephone calls and, if necessary, a 
certified letter to the subject’s  last known mailing address or  local equivalent methods).  
These contact attempts should be docume nted in the subject ’s medical record. 
 Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the study.  
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 38 8.0 STUDY ASSESSMENTS AND PROCEDURES 
This section provides a high-level summary of the study assessments to be performed.  For 
details as to when these assessment s are performed see the SoA (Section 1.3) 
 Study procedures and their timi ng are summarized in Section 1.3.  
 Protocol waivers or exem ptions are not allowed. 
 Immediate safety concerns s hould be discussed with the S ponsor designee immediately upon 
occurrence or awareness to determine if the pa rticipant should conti nue or discontinue study 
treatment. 
 Adherence to the study design requ irements, including those specified  in the SoA, is essential 
and required for study conduct. 
 All screening evaluations must be complete d and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The Investigator will maintain a screening log to 
record details of all participants screened a nd to confirm eligibility or record reasons for 
screening failure, as applicable.  
 Procedures conducted as part of  the subjects’ routin e clinical management (eg, blood count) 
and obtained before signing of the ICF may be utilized for screening or baseline purposes 
provided the procedures met the protocol-specified criteria a nd were performed within the 
time frame defined in the SoA. 
 The maximum amount of blood collected from each subject over the duration of the study, 
including any extra assessments that may be required, will not exceed 450 mL.  Repeat or 
unscheduled samples may be taken for safety reasons or for technical issues with the 
samples. 
8.1 Efficacy Assessments  
This is a Phase 1 safety study, th ere are no efficacy  assessments. 
8.2 Safety Assessments  
Planned time points for all safety asse ssments are provided in the SoA (Section 1.3). 
8.2.1 Physical Examinations 
 A complete physical examination will be performed to assess any physical abnormalities and 
will include at a minimum, assessments of th e following body systems: general appearance, 
overall status of the skin, head, neck, trunk, eyes, heart and lungs (eg, breathing sounds), 
abdomen, extremitie s, lymph nodes. 
 Height and weight wi ll also be measured  and recorded at the Screening visit. 
 Investigators should pay special attention to clinical signs related to previous serious 
illnesses. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 39 8.2.2 Vital Signs 
Vital signs are to be taken before blo od collection for laboratory tests.   
 Systolic and diastolic blood pressu re (mmHg):  to be assessed af ter a participant has been at 
rest (seated) for at least 5 mi nutes in a quiet setting without distractions (eg, television, cell 
phones) with a completely automated device.  Manual techniques will be used only if an 
automated device is not available.  A total of  3 consecutive blood pressure readings will be 
recorded at intervals of at least 1 minute.  The average of the 3 blood pressure readings will 
be recorded on the eCRF.  
 Pulse rate (beats/minute): to be assessed after a subject has been at rest (seated) for at least 
5 minutes in a quiet setting without distractions (eg, te levision, cell phones) with a 
completely automated device.  Manual techniques  will be used only if an automated device is 
not available. A total of 1 pulse  reading should be recorded.  
 Respiration rate (per minute)  will be measured by counting at least 30 seconds and 
multiplying accordingly.  Respiration rate may be taken concurrently with all ECGs. 
 Oral temperature (as Fahrenheit de grees) will be assessed and recorded. 
8.2.3 Electrocardiograms 
 A single 12-lead ECG will be performed at the Sc reening visit to ensure that a study subject 
does not have, in the Investigator ’s clinical judgement , a clinically signifi cant condition or a 
condition that may pose an unacceptable safe ty risk for particip ation in the study.  
 For subjects in Cohort A, a single 12-lead ECG will be collected on Day 1 prior to the first 
dose and on the study exit visit (Day 21).  
 For subjects in Cohort B, triplicate 12-lead ECGs  will be collected at subsequent visits as 
outlined in the SoA (see Section 1.3) using an ECG machine that automatically calculates the 
heart rate and measures PR, QR S, QT, and QTc intervals.  
 In cases where ECG and PK sampling overlap, ECGs  should be collected fi rst, to ensure that 
PK samples are collected at the scheduled time point. 
 At each time point at which tr iplicate ECGs are required, 3 in dividual ECG tracings should 
be obtained as closely as possi ble in succession, but no more than  2 minutes apart.  The full 
set of triplicates should be co mpleted in less than 4 minutes. 
 ECGs will be assessed by a central ECG reading center.  A cardiologist will review 
screening, pre- and post-treatment ECGs and discuss any abnormal findings with the 
Investigator, as appropriate. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 40 8.2.4 Clinical Safety Laboratory Assessments 
 See Appendix 3  for the list of clinical laboratory test s to be performed and to the SoA for the 
timing and frequency.  
 The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during th e study in the AE section of the eCRF.  The 
laboratory reports must be file d with the source documents.  Clinically significant abnormal 
laboratory findings are those th at are not associated with the underlying disease, unless 
judged by the Investigator to be more severe than expected for the subject’s condition. 
 All laboratory tests with values considered  clinically significa ntly abnormal during 
participation in the study should be repeated unti l the values return to normal or baseline or 
are no longer considered clin ically significant by the Inves tigator or Medi cal Monitor. 
 If such values do not return to normal/b aseline within a pe riod of time judged 
reasonable by the Investigator, the etiol ogy should be identified, and the Sponsor 
notified. 
 All protocol-required laboratory assessments, as defined in Appendix 3 , must be 
conducted in accordance with the Laboratory Manual and the SoA.  
 If laboratory values from non- protocol-specified laborator y assessments performed at 
the institution’s local laboratory require a change in subject management or are 
considered clinically sign ificant by the Investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the eCRF.  
8.2.5 Otoscopy 
Otoscopy will be performed to assess the appe arance of the tympanic membrane (normal or 
abnormal).  If abnormal, then  it will be rated for the following variables:   
 Contour (retracted, full, bulging, perforated).  
 Color (partly red or completely red).  
 Color of fluid behind the tympanic membrane (ye llow, dark red, bright red, green, or clear). 
 Translucency (semi-opaque, opaque).   
8.2.6 Tympanometry  
Tympanometry will be performed  to assess tympanic membrane  mobility, ET function and ME 
function by measuring the amount of sound energy re flected back when a small probe is placed 
in the ear canal ( Rosenfeld et al, 2016 ).  The output of the right ear  and left ear tympanometry 
will be a tympanogram tracing cl assified as Type A (normal), Type B (abnormal) or Type C 
(abnormal) ( Jerger, 1970 ). 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 41 8.2.7 Nasal and Epipharynx Endoscopy  
Nasal and epipharynx endoscopy will be assesse d for normal or abnormal appearance. Under 
abnormal, the following crit eria should be assessed: 
 Swelling 
 Redness 
 Bleeding 
 Rhinorrheoea (nose only) 
 Other  
At the Screening visit, as a part of the nasa l endoscopy, the length of th e nasal cavity (in mm) 
will be recorded separately for the left and right si de.  The length of the nasal cavity is defined as 
the distance from the tip of the nos e to the entry point of the ET. 
For all other scheduled assessments, the nasal an d epipharynx endoscopy assessment should be 
done prior to the first dose of the day. 
8.2.8 Olfactory Test  
An olfactory test, UPSIT, will be performed at th e Screening (Day -28 to Day -1) visit to ensure 
that a subject does not have a clinically signi ficant condition or a condi tion that may pose an 
unacceptable safety risk for participation in the study.  At the Day 8 and Day 14 visits, an 
olfactory test will be performed to assess for abno rmal olfactory function after the dosing period.  
If abnormal findings are present at  the Day 14 visit, then an a dditional olfactory test will be 
performed at the Day 21 study exit visit.  
The UPSIT test consists of 4 booklets containi ng 10 odorants apiece, 1 odorant per page.  The 
stimuli are embedded in 1 µm to 50 µm diameter  microencapsulated crystals located on brown 
strips at the bottom of each page.  Above each odorant strip is a multiple-choice question with 
4 alternative responses for each ite m.  For example, 1 of the items reads, “This odor smells most 
like: a) chocolate; b) banana; c) onion; or d) fruit punch.”  The response “banana” is correct in 
this case.  The subject is required to answer 1 of  the 4 alternatives, even if no smell is perceived 
(ie, the test is forced-choice).  This helps to  encourage the subject to sample each odorant and 
provides a basis for the detection of malingering.  To ensure uni formity in test administration, 
the test booklets should be administered in ch ronologic order, eg, bookl et 1, booklet 2, etc. 
(Doty 1984 ).  A total UPSIT score of <35 is abnorm al for females and a total score <34 is 
abnormal for males.  In this study we intend to determine if there is any cha nge from ‘normal’ (at 
baseline) to ‘abnormal’ post-treatme nt.  If such a change occurs it will be captured as an AE.  
The severity of the AE will be assessed as per the resulting ‘olfactory diagnosis’ in the following 
table: 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 42 Test Score Olfactory Diagnosis 
00-05 Probable Malingering 
06-18 Total Anosmia 
19-25 Severe Microsmia 
26-29 Moderate Microsmia (males) 
26-30 Moderate Microsmia (females) 
30-33 Mild Microsmia (males) 
31-34 Mild Microsmia (females) 
34-40 Normosmia (males) 
35-40 Normosmia (females) 
 
8.2.9 Audiology Pure Tone Hearing Test 
An audiology pure tone hearing test will be perform ed at the Screening (Day -28 to Day -1) visit 
to ensure that a subject does not have clinical ly significant abnormal hear ing.  Average pure tone 
hearing loss at 4 frequencies (500, 1000, 2000 and 4000 Hz) ranges from normal hearing to 
moderate hearing loss (0- 55 dB) will be tested.  The 50th per centile is about 25 dB hearing level 
(HL).  Average pure tone audiometry will be perf ormed as per the audiol ogy testing template in 
Appendix 10 .  The hearing test should be performed  in a quiet environment, preferably a 
separate closed or sound-proofed area set asid e specifically for that purpose.  Comprehensive 
audiologic evaluation is recommended for a nyone who fails the pure tone hearing test.  
Audiologic assessment include s evaluating air-conduction and bone-conduction thresholds for 
pure tones, speech detection or speech recogni tion thresholds, and measurements of speech 
understanding, if possible ( Rosenfeld et al, 2004 ). 
8.3 Adverse Events 
The definitions of an AE or SAE can be found in Appendix 4 . 
Adverse events will be reported by the subject. 
The Investigator and any desi gnees are responsible for dete cting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatment or study procedur es, or that caused the 
subject to discontinue the  study treatment or the study  (see Section 4.6 and 7.0). 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 43 8.3.1 Time Period and Frequency for Co llecting AE and SAE Information  
All SAEs will be collected from th e time first exposure to the st udy treatment until the study exit.  
All AEs will be collected  from the time first exposure to th e study treatment unt il the study exit.  
Medical occurrences that begin before the star t of study treatment but after obtaining informed 
consent will be recorded as pre-treatment-emergent AEs in the AE section of the eCRF. 
All SAEs will be recorded and reported to the Sp onsor or designee within 24 hours, as indicated 
in Appendix 4 .  The Investigator will submit any upda ted SAE data to the Sponsor within 
24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the Investigator learns  of any SAE, including a death, at any time after 
a subject has been discharged from the study, and he/she considers the event to be reasonably 
related to the study treatment or study participation, the Investig ator must promptly notify the 
Sponsor. 
The method of recording, evaluati ng, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 4 . 
8.3.2 Method of Detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of  the subject is the prefer red method to inquire about 
AE occurrences.  
8.3.3 Follow-up of AEs and SAEs 
After the initial AE/SAE report, the Investigator is required to proactivel y follow each subject at 
subsequent visits/contacts. All AEs/SAEs will be followed until resolu tion, stabilization, the 
event is otherwise explained, or  the subject is lost to foll ow-up (as defined in Section 7.3). 
Further information on follow- up procedures is given in Appendix 4 . 
8.3.4 Regulatory Reporting Requirements for SAEs 
 Prompt notification by the Investigator to the Sponsor of an  SAE is essential so that legal 
obligations and ethical responsibil ities towards the safety of subj ects and the safety of a study 
treatment under clinical investigation are met.  
 The Sponsor has a legal responsibility to notify both the local regulator y authority and other 
regulatory agencies about the safety of a st udy treatment under clinic al investigation. The 
Sponsor will comply with country-specific regulatory requirements relating to safety 
reporting to the regulatory aut hority, Institutional Review Boar ds (IRB)/Independent Ethics 
Committees (IEC), and Investigators. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 44  Investigator safety reports mu st be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to  local regulatory requirements and Sponsor policy and 
forwarded to Investigators as necessary. 
 An Investigator who receives an Investigator  safety report descri bing an SAE or other 
specific safety information (eg, summary or li sting of SAEs) from th e Sponsor will review 
and then file it along with the IB and will not ify the IRB/IEC, if appropriate according to 
local requirements. 
8.3.5 Pregnancy 
For purposes of this study, a woman will be considered of childbearing potential unless 
documentation indicates she is pe rmanently sterilized (ie, hyste rectomy, bilateral salpingectomy 
or bilateral oophorectomy) or is naturally postmenopausal.  Natura l menopause is defined as the 
permanent cessation of menstrual periods, determined retrospectiv ely after a woman who is at 
least 40 years of age has expe rienced 12 months of amenorrh ea without any other obvious 
pathological or physiological cau se.  Female subjects who are pe rmanently sterilized or are 
naturally postmenopausal will not be require d to use contraceptives during the study.  
The Investigator will review the contracepti on requirements for the study with each WOCBP 
who is considering being a subject. 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception cons istently and correctly  as described in Appendix 6.  
Details of all pregnancies in female subjects w ill be collected after the start of study treatment 
and until the study exit.  If a pregnancy is report ed, the Investigator should inform the Sponsor 
designee within 24 hours of learni ng of the pregnancy and should fo llow the procedures outlined 
in Appendix 6 . 
The Investigator will (1) notify the subject’s physic ian that the subject was enrolled in the study 
and treated with an investiga tional drug OP0201 or placebo, and (2) follow the progress of the 
pregnancy to term.  The Investig ator must document the outcome of the pregnancy and provide a 
copy of the documentation to the Sponsor. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, st illbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
8.3.6 Adverse Events of Special Interest 
Not applicable. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 45 8.3.7 Medical Device Incidents (I ncluding Malfunctions) 
Instructions for documenting Medica l Device Incidents are provided in Appendix 9 .  
Medical devices are being provided for use in this study for delivering the study treatment via 
MDI.  In order to fulfill regulatory reporting obligations worldwide, the Investigator is 
responsible for the detection and documentation of events meeting th e definitions of  incident or 
malfunction that occur during th e study with such devices.  
The definition of a Medical De vice Incident can be found in Appendix 9 . 
NOTE: Incidents fulfilling the definition of an AE /SAE will also follow the processes outlined in 
Section 8.3.3  and Appendix 4 of the protocol.  
8.3.7.1  Time Period for Detecting Medical Device Incidents 
 Medical Device Incidents or malfunctions of th e device that result in  an incident will be 
detected, documented, and repor ted during all periods of th e study in which the medical 
device is used.  
 If the Investigator learns of a ny incident at any time after a participant has been discharged 
from the study, and such incident is consid ered reasonably relate d to a medical device 
provided for the study, the Investigat or will promptly notify the Sponsor. 
The method of documenting Medical De vice Incidents is provided in Appendix 9 . 
8.3.7.2  Follow-up of Medical Device Incidents 
 All Medical Device Incidents involving an AE will be followed and reported in the same 
manner as other AEs (see Appendix 4 ).  This applies to all su bjects, including those who 
discontinue study treatment. 
 The Investigator is respon sible for ensuring that follo w-up includes any supplemental 
investigations as indicated to elucidate th e nature and/or causal ity of the incident. 
 New or updated information will  be recorded on the original ly completed form with all 
changes signed and dated by the Investigator. 
8.3.7.3  Prompt Reporting of Medical Device Incidents to Sponsor 
 Medical Device Incidents will be reported to the Sponsor within 24 hours after the 
Investigator determines that the event meet s the protocol definiti on of a Medical Device 
Incident. 
 The Medical Device Incident Report Form will be  sent to the Sponsor by email. If email is 
unavailable, then standard  post should be utilized. 
 The same individual will be the contact for th e receipt of medical de vice reports and SAE. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 46 8.3.7.4  Regulatory Reporting Requirements  for Medical Device Incidents 
 The Investigator will promptly report all in cidents occurring with any medical device 
provided for use in the study in order for the Sp onsor to fulfill the le gal responsibility to 
notify appropriate regulatory au thorities and other entities about certain safety information 
relating to medical devices bei ng used in clinical studies. 
The Investigator, or responsible person accordin g to local requirements (eg, the head of the 
medical institution), will comply with the applicab le local regulatory requirements relating to the 
reporting of incident s to the IRB/IEC. 
8.4 Treatment of Overdose 
It is unknown what dose of study treatment within  a 24-hour time period would be considered an 
overdose.  Both active ingredients in th e study treatment are endogenous to the human 
respiratory system in very large quantities co mpared with the maximu m study treatment dose of 
40 mg per day of surfactant.  Even if a subject were to administer an en tire canister of the study 
treatment into the nostrils in 1 day, the total exposure to the active pharmaceutical ingredient 
would be 250 mg (approximately 3.6 mg/kg for a 70 kg adult), which is far less than exposures 
on a mg/kg basis for approved surf actant products that are usually  given over 1 to 2 days (see 
Table 5 of the IB). 
HFA-134a is not endogenous to the human respirator y system.  As noted in Section 4.3.2 of the 
IB, misuse or intentional inhalation abuse may cause death without warning symptoms, due to 
cardiac effects.  Other symptoms potentially relate d to misuse or inhalation abuse are: anesthetic 
effects, light-headedness, dizzine ss, confusion, incoordination, drowsiness, or unconsciousness, 
irregular heartbeat with a strange  sensation in the chest, heart thumping, apprehension, feeling of 
fainting, dizziness or weakness.  Vapors are heavier than air and can cause suffocation by 
reducing oxygen available for breathing.  Ho wever, the maximum amount of 10 mL of 
HFA-134a per study treatment canister would not be  sufficient exposure to be considered an 
overdose.  If symptoms described above were ex perienced with a suspected HFA-134a overdose, 
the suggested treatment would be to deliver oxyg en and other necessary supportive care per the 
Investigator’s judgement.  
In the event of an overdose,  the Investigator should: 
 Contact the Medical Monitor immediately. 
 Closely monitor the participan t for any AE/SAE and laborator y abnormalities for at least 
2 days. 
 Document the quantity of the excess dose as well as the duration of the overdose in the 
eCRF. 
Decisions regarding dose interruptions or modifi cations will be made by the Investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the subject. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 47 8.5 Pharmacokinetics 
Planned time points for all PK assess ments are provided in the SoA (Section 1.3). 
8.5.1 Collection of Samples 
On Days 1 and 14, blood samples will be collec ted for the determination of DPPC and CP 
concentrations only for subjects in Cohort B.  The SoA (Section 1.3) presents the schedule for 
blood collection.  Time 0 is defined as the time of the study treatme nt administration.  
The timing of scheduled samples may be adjusted  according to clinical needs or needs for PK 
data.  The actual collection tim es must be recorded.  The tim e and date of study treatment 
administration will also be recorded.  Instructio ns for the collection and handling of biological 
samples will be provided by the Sponsor or desi gnee.  Blood samples will be collected via a 
venous cannula or direct venipuncture.  Samples w ill be collected, labeled, stored, and shipped as 
detailed in the Laboratory Manual.  The total volume of bloo d taken for PK and 
pharmacodynamic sampling during the study will not exceed 450 mL.  For specific sampling 
volumes, please refer to  the Laboratory Manual. 
The 5-minute PK sample should be collected with in ±2 minutes of the scheduled time and the 
20-minute PK sample should be collected within +5  minutes of the scheduled time.  All other PK 
samples should be collected within ±5 minutes of the scheduled time. 
8.5.2 Determination of Drug Concentration 
Samples for the determination of  DPPC and CP in serum will be analyzed on behalf of the 
Sponsor by xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx using appropriate validated bioanalytical 
methods.  Full details of the bioanalytical method s will be described in a separate Bioanalytical 
Report. 
All samples still w ithin the known stability of DPPC and CP at the time of receipt by the 
bioanalytical laboratory will be analyzed. 
Baseline samples collected from su bjects who received placebo will be analyzed to establish the 
endogenous DPPC and CP concentrations.  Samp les collected after dos ing from subjects who 
received placebo will not be analyzed. 
Samples collected for analyses of DPPC and CP concentration may also be used to evaluate 
safety aspects related to concerns  arising during or  after the study. 
8.5.3 Calculation of Derivation of Pharmacokinetic Variables 
Pharmacokinetic parameters will be derived using noncompartmental methods with Phoenix® 
WinNonlin® Version 6.4 or higher (Certata, L.P. Princeton, New Jersey , US) and/or SAS® 
Version 9.2 or higher (SAS Institute, Inc., Cary, North Carolina, US). Actual elapsed time from 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 48 dosing and baseline adjusted DPPC and CP concen trations will be used for the final serum PK 
parameter calculations. 
Serum Pharmacokinetic Parameters 
The PK parameters in Table 6 will be determined for serum DPPC and CP on Day 14, when 
possible. 
Table 6 Serum Blood Pharmacokinetic Parameters 
Pharmacokinetic Parameter Definition 
Cmax Maximum concentration, obtained di rectly from the baseline adjusted 
concentration versus time data. 
tmax Time to C max. 
 
Additional serum parameters may be calculated if deemed appropriate. 
Drug concentration information that may unblin d the study will not be reported to the study 
center or study personnel until the study has been unblinded. 
8.6 Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study. 
8.7 Genetics 
Genetics are not evaluated in this study. 
8.8 Biomarkers 
Biomarkers are not eval uated in this study. 
8.9 Health Economics 
Health Economics parameters are not evaluated in this study. 
9.0 STATISTICAL CONSIDERATIONS 
9.1 Statistical Hypotheses 
Not applicable. 
9.2 Sample Size Determination  
The sample size is not based on stat istical considerations, but is typi cal for studies of this nature, 
and is considered adequate to characteri ze the distribution of the planned endpoints. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 49 There will be a total of 30 subjects; 2 dose cohorts of 15 subjects each.  Subjects will be 
randomized in 4:1 (OP0201:placebo) ratio to re ceive either OP0201 or placebo within each dose 
cohort. 
9.3 Populations for Analyses 
For purposes of analysis, the analysis sets in Table 7 are defined. 
Table 7 Analysis Sets 
Analysis Set Description 
Entered Analysis Set All subjects who sign the informed consent form. 
Safety Analysis Set All subjects who receive any study treat ment (OP0201 or placebo). Subjects 
will be analyzed according to the treatment they received. 
Pharmacokinetic Analysis Set All subjects in Cohort B who received at least 1 dose of OP0201 and have 
1 quantifiable serum DPPC or CP concentration collected post-dose without 
important protocol deviations/violations or events thought to significantly 
affect the pharmacokinetics. 
CP = cholesteryl palmitate; DPPC = dipalmitoylphosphatidylcholine 
 
9.4 Statistical Analyses 
The Statistical Analysis Plan (SAP) will be deve loped and finalized before database lock and 
will describe the subject analysis sets to be included in the analyses, and procedures for 
accounting for missing, unused, and spurious data. This section is a summary of the planned 
statistical analyses of the pr imary and secondary endpoints. 
All analyses (with the exception of PK parameter analysis), summaries, and listings will be 
performed using SAS softwa re (Version 9.4 or higher). 
Descriptive statistics, including the following, will be used as a pplicable to summarize the study 
data: 
 Continuous variables: sample size (n), mean, standard devi ation (SD), median, minimum 
(min), and maximum (max). 
 Categorical variables: fre quencies and percentages. 
Individual subject data will be presented in listings. 
9.4.1 Efficacy Analyses 
Not applicable. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 50 9.4.2 Pharmacokinetic Analyses 
Pharmacokinetic analyses will be described in th e SAP that will be finalized before database 
lock. All PK analyses will be pe rformed on the PK Analysis Set. 
Observed and baseline adjusted serum DPPC concentrations will be summarized by time point. 
Observed and baseline adjusted serum CP conc entrations (if available) will be summarized by 
time point. 
Serum DPPC PK parameters (if any) will be  summarized. Serum CP PK parameters (if 
available) will be summarized. 
9.4.3 Safety Analyses 
All safety analyses will be perform ed on the Safety Analysis Set. 
Treatment-emergent adverse events (TEAEs) are defined as AEs that  first occurred or worsened 
in severity after administ ration of study treatment. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). For each study treatment, numbers of TEAEs and incidence rates will be tabulated 
by preferred term and system organ class. 
Treatment-emergent AEs by maximum severity, TEAEs by relationship to study treatment, 
SAEs, TEAEs leading to death, a nd TEAEs leading to discontinua tion of study treatment will be 
tabulated for each study treatment.  
All laboratory test results, vital signs measurements, and ECG results will be summarized for 
each treatment group using descriptive statistics at each visit for raw numbers and change from 
baseline. 
Test results from otoscopy, ty mpanometry, nasal and epipha rynx endoscopy, UPSIT olfactory 
test, and audiology pure tone h earing test will be listed a nd summarized as appropriate. 
Additional details will be provided in SAP. 
9.4.4 Missing Data 
Missing data, if any, will be described in the SAP. 
9.5 Interim Analyses  
No interim analysis is planned. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 51 9.6 Safety Review Committee 
After all subjects in Cohort A have completed th e Day 14 visit, a SRC will review all the blinded 
safety data to determine whether the doses admini stered are safe and well tolerated and to make a 
recommendation to escalate to th e next cohort (Cohort B) or not. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 52 10.0 REFERENCES 
Chandrasekhar SS, Otitis media: Treatment with intranasal aerosolized surfactant. Laryngoscope 
2004; 114:472-485. 
Chonmaitree T, Revai K, Grady JJ,  Clos A, Patel JA, Nair S, Fan J, Henrickson KJ. Viral upper 
respiratory tract infection and otitis media complication in y oung children. Clin Infect Dis 2008; 
46:815-23. 
Colacicco G, Basu MK. Effects of cholesterol and cholesteryl ester on dynamic surface tension 
of dipalmitoyl le cithin. J Colloid Interface  Sci 1977; 61(3):516-518. 
Doty RL, Shaman P, Kimmelman CP, Dann MS. Univ ersity of Pennsylvani a smell identification 
test: A rapid quantitative olfa ctory function test for the c linic. Laryngoscope 1984; 94:176-178. 
Jerger J. Clinical experience with impedance audiometry. Ar ch Otolaryngol 1970; 92(4):311-24. 
Notter RH. Lung Surfactants: Basic science and clinical applications . Published by Marcel 
Dekker, Inc. 2000. 
Reznik GK. Comparative anatomy, physiology, a nd function of the upper respiratory tract. 
Environ Health Perspect 1990; 85:171-176. 
Rosa-Olivares J, Porro A, Rodriguez-Varela M, Riefkohl G, Niroomand-Rad I. Otitis media: To 
treat, to refer, to do nothing: A review for the practitioner. Pediat r Rev 2015; 36(11):480-486. 
Rosenfeld RM, Culpepper L, Yawn B, Ma honey MC; AAP, AAFP, AAO-HNS Subcommittee 
on Otitis Media with Effusion. Oti tis media with effusion clini cal practice guideline. Am Fam 
Physician. 2004 Jun 15;69(12):2776, 2778-9. 
Rosenfeld RM, Shin JJ, Schwartz SR, Coggins R, Gagnon L, Hackell JM, Hoelting D, Hunter 
LL, Kummer AW, Payne SC, Poe DS, Veling M, Vila PM, Walsh SA, Corrigan MD. Clinical 
practice guideline: Otitis media with effusi on (update). Otolaryngol Head Neck Surg 2016; 
154(1S):S1-S41. 
Rovers MM, Schilder AGM, Zielhuis GA, Rosenfeld RM. Otitis media. Lancet 2004; 
363:465-473. 
Schilder AGM, Chonmaitree T, Cripps AW, Ro senfeld RM, Casselbrant ML, Haggard MP, 
Venekamp RP. Otitis Media Prime r. Nature Reviews 2016; 2:1-18. 
Seibert JW, Danner CJ. Eustachian tube function  and the middle ear. Otolaryngol Clin North 
Am. 2006; 39(6):1221-1235. 
Taeusch HW, Lu K, Ramierez-Scrempp D. Impr oving pulmonary surfactants. Acta Pharmacol 
Sin 2002 Oct; 23 Supplement: 11-15. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 53 Thomas JP, Berner R, Zahnert T, Dazert S. Acut e otitis media – A structured approach. Dtsch 
Arztebl Int 2014; 111(9):151-160. 
US FDA Drug Study Designs - Informat ion Sheet; retrieved January 23, 2017, 
http://www.fda.gov/regulatoryinfo rmation/guidances/ucm126501.htm. 
US FDA Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension and Spray 
Drug Products, July 2002 
Weber R, Garcia J, Faruqi R, Banerji D, George s G; 405 Investigator Group. Safety and clinical 
relief over 1 year with triamcinolone acetonide hydrofluoroalk ane-134a nasal aerosol in patients 
with perennial allergic rhinitis. Allergy Asthma Proc. 2006; 27(3):243-247. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 54 11.0 APPENDICES 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 55 Appendix 1 Abbreviations 
Term/Abbreviation Definition 
AE Adverse event 
ALP Alkaline phosphatase  
ALT Alanine aminotransferase 
AOM Acute Otitis Media  
Cmax Maximum concentration 
CRF Case Report Form 
CP Cholesteryl palmitate  
DPPC Dipalmitoylphosphatidylcholine 
ECG Electrocardiogram 
EaT Early termination 
ET Eustachian tube  
eCRF Electronic case report form 
EU European Union 
FSH Follicle stimulating hormone  
FDA Food and drug administration 
GCP Good Clinical Practice 
GMP Good Manufacturing Processes  
HL Hearing level   
HRT Hormonal replacement therapy  
IB Investigator’s Brochure 
ICH International C ouncil for Harmonisation 
ICF Informed consent form  
INR International normalized ratio  
IP Investigational product  
IEC Independent Ethics Committee 
IRB Institutional Review Board 
MDI Metered dose inhaler  
ME Middle ear 
PK Pharmacokinetics 
OM Otitis Media 
OME Otitis Media with Effusion  
RDS Respiratory distress syndrome  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 56 SAE Serious adverse event 
SAP Statistical Analysis Plan  
SoA Schedule of Assessments 
SRC Safety Review Committee  
tmax Time to C max 
TEAE Treatment-emergent adverse event 
TID Three times a day 
ULN Upper limit of normal  
US United States 
UPSIT University of Pennsylva nia Smell Inventory Test  
WOCBP Woman of chil dbearing potential  
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 57 Appendix 2 Regulatory, Ethical, and Study Oversight Considerations 
Regulatory and Ethical Considerations 
 This study will be conducted in accordance w ith the protocol and with the following: 
 Consensus ethical principles derived fro m international guide lines including the 
Declaration of Helsinki and Council for International Organi zations of Medical 
Sciences International Ethical Guidelines. 
 Applicable ICH Good Clinical  Practice (GCP) Guidelines. 
 Applicable laws and regulations. 
 The protocol, protocol amendm ents, ICF, Investigator Br ochure, and other relevant 
documents (eg, advertisements) must be submi tted to an IRB/IEC by the Investigator and 
reviewed and approved by the IRB/IE C before the study is initiated.  
 Any amendments to the protoc ol will require IRB/IEC and regulatory authority approval, 
when applicable, before implementation of changes made to the study design, except for 
changes necessary to eliminate an  immediate hazard to subjects.  
 The Investigator will be res ponsible for the following: 
 Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC. 
 Notifying the IRB/IEC of SAEs or other sign ificant safety findings as required by 
IRB/IEC procedures. 
 Providing oversight of the c onduct of the study at the study center and adherence to 
requirements of 21 Code of Federal Regulatio ns (CFR), ICH guideli nes, the IRB/IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations. 
 After reading the protocol, each Investigator w ill sign the protocol signature page and send a 
copy of the signed page to the Sponsor or representative ( Appendix 12 ). The study will not 
start at any study center at which the Investigator has not signed the protocol. 
Adequate Resources 
The Investigator is responsible fo r supervising any indivi dual or party to w hom the Investigator 
delegates study-related duties and func tions conducted at the study center. 
If the Investigator/institution retains the servi ces of any individual or party to perform 
study-related duties and functions, the Investigator/institution shoul d ensure this individual or 
party is qualified to perfor m those study-related duties and functions and should implement 
procedures to ensure the integrity of the st udy-related duties and functions performed and any 
data generated. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 58 Financial Disclosure 
Investigators and sub-Investigators will provide the Sponsor with suffic ient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appr opriate regulatory author ities. Investigators are 
responsible for providing information on financial interests du ring the course of the study and for 
1 year after comple tion of the study. 
Insurance 
The Sponsor has obtained liability insurance, wh ich covers this study as  required by local law 
and/or national regulations and/ or ICH guidelines, whichever is applicable. The terms of the 
insurance will be kept in the study files. 
Informed Consent Process 
 The Investigator or his/her representative will ex plain the nature of the study to the subject or 
his/her legally authorized representative and answer all questions regarding the study.  
 Subjects must be informed that  their participation is voluntar y. Subjects or their legally 
authorized representative will be required to si gn a statement of informed consent that meets 
the requirements of 21 CFR 50, local regula tions, ICH guidelines, Health Insurance 
Portability and Accountability Act requirements,  where applicable, a nd the IRB/IEC or study 
center.  
 The medical record must include a statement that written informed  consent was obtained 
before the subject was entered in the study a nd the date the written consent was obtained. 
The authorized person obtain ing the informed consent must also sign the ICF. 
 Subjects must be re-consented to the most current version of the ICF(s) during their 
participation in the study.  
 A copy of the ICF(s) must be provided to the subject or th e subject’s legally authorized 
representative.  
Data Protection 
 Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets 
that are transferred to the Sponsor will contai n the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
 The subject must be informed that his/her personal  study-related data will be used by the 
Sponsor in accordance with local data protecti on law. The level of disclosure must also be 
explained to the subject.  
 The subject must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other author ized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by in spectors from regul atory authorities. 
 The ICF will incorporate (or, in some cases, be accompanied by a separate document 
incorporating) wording that co mplies with relevant data prot ection and privacy legislation. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 59  The Sponsor or its representative  will not provide indi vidual genotype results  to subjects, any 
insurance company, any employer,  their family members, ge neral physician, or any other 
third party, unless required to do so by law. 
 Extra precautions are taken to preserve confiden tiality and prevent gene tic data being linked 
to the identity of the subject. In exceptiona l circumstances, however, certain individuals 
might see both the genetic data and the personal identi fiers of a subject. For example, in the 
case of a medical emergency, the Sponsor or representative p hysician or an Investigator 
might know a subject’s identity and also have  access to his or her genetic data. Also, 
regulatory authorities may require access to the relevant files. 
Administrative Structure 
The safety committee will incl ude, at a minimum, the Sponsor ’s responsible physician (or 
designated Medical Monitor) and the Principal Investigator. The Principal Investigator and the 
Sponsor, when appropriate, will invite other specia list individuals to participate in the review, eg, 
PK scientists, statisticians, clinical specialists etc. 
Medical Monitor 
xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxx 
Dissemination of Clinical Study Data 
The results of the study should be reported within 1 year from the end of the clinical study. The 
study will be registered on clin icaltrials.gov and appropriate repor ting to ensure compliance with 
clinicaltrials.gov will be met. 
Data Quality Assurance 
 All subject data relating to th e study will be recorded on printe d or eCRFs unless transmitted 
to the Sponsor or designee electr onically (eg, laboratory data). The Investigator is responsible 
for verifying that data entries are accurate a nd correct by physically or  electronically signing 
the case report form (CRF).  
 The Investigator must maintain accurate do cumentation (source da ta) that supports the 
information entered in the CRF.  
 The Investigator must perm it study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
 The Sponsor or designee is res ponsible for the data manageme nt of this study including 
quality checking of the data.  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 60  Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized study center personn el are accurate, complete, and verifiable 
from source documents; that the safe ty and rights of subjects ar e being protected; and that the 
study is being conducted in accordance with th e currently approved protocol and any other 
study agreements, ICH GCP, and all a pplicable regulatory requirements.  
 Records and documents, including signed ICFs, pe rtaining to the conduct of this study must 
be retained by the Investigator for 15 years after study completion unle ss local regulations or 
institutional policies require a longer retenti on period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another locati on or party without written not ification to the Sponsor.  
Source Documents 
The Investigator/institution should maintain adeq uate and accurate source documents and study 
records that include all pertinen t observations on each of the study center’s subjects. Source data 
should be attributable, legible,  contemporaneous, original, accurate, and complete. Changes to 
source data should be traceable, should not obscure the original entry, and should be explained if 
necessary (eg, via an audit trail). 
 Source documents provide evidence for the exis tence of the subject and substantiate the 
integrity of the data collected. Source documents  are filed at the Inve stigator’s study center. 
 Data reported on the CRF or entered in the e CRF that are transcribe d from source documents 
must be consistent with the source documents or the discrepancies mu st be explained. The 
Investigator may need to request  previous medical records or transfer records, depending on 
the study. Also, current medical records must be available. 
Study and Study Center Closure 
The Sponsor designee reserves the right to close the study center or term inate the study at any 
time for any reason at the sole di scretion of the Sponsor. Study cen ters will be closed upon study 
completion. A study center is considered closed when all required documents and study supplies 
have been collected and a study cente r closure visit has been performed. 
The Investigator may init iate study center closure at any time , provided there is reasonable cause 
and sufficient notice is given in ad vance of the intended termination. 
Reasons for the early closure of a study center by the Sponsor or Investigator may include but 
are not limited to: 
 Failure of the Investigator to comply with th e protocol, the requireme nts of the IRB/IEC or 
local health authorities, the Sponsor ’s procedures, or GCP guidelines. 
 Inadequate recruitment of s ubjects by the Investigator. 
 Discontinuation of further st udy treatment development. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 61 Publication Policy 
The Sponsor will comply with the requirements for publication of study results.  In accordance 
with standard editorial and une thical practice. Novus Therapeu tics, Inc, as the Sponsor, has 
proprietary interest in the study and thus w ill be involved in reviewing, at a minimum, any 
abstract or manuscript prior to submission in order to allow the Sponsor to protect proprietary 
information and to provide comments.  For this  study, authorship and ab stracts or manuscript 
composition will reflect joint c ooperation between the Investigator and Novus Therapeutics, Inc. 
personnel.  Authorship will be 1) established prio r to the writing of abst racts or manuscripts, 
2) determined by mutual agreement and 3) in line with International Committee of Medical 
Journal Editors authorship requirements. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 62 Appendix 3 Clinical Laboratory Tests  
 The tests detailed in Table 8 will be performed by the central laboratory/by the local 
laboratory.  
 Local laboratory results are only required in the event that the central laboratory results are 
not available in time for eith er study treatment administratio n and/or response evaluation. If a 
local sample is required, it is important that th e sample for central analysis is obtained at the 
same time. Additionally, if the local laborator y results are used to make either a study 
treatment decision or response evaluation, th e results must be entered into the CRF. 
 Protocol-specific requirements  for inclusion or exclusion of subjects are detailed in 
Section 5.0 of the protocol. 
 Additional tests may be performed at any time  during the study as de termined necessary by 
the Investigator or requ ired by local regulations. 
Table 8 Protocol-required Safe ty Laboratory Assessments 
Laboratory 
Assessments Parameters 
Hematology Platelet Count   White Blood Cell Count with Differential: 
 Red Blood Cell Count Neutrophils 
 Hemoglobin Lymphocytes 
 Hematocrit  Monocytes 
 Red Blood Cell Indices: Eosinophils 
 Mean corpuscular volume (MCV) Basophils 
 Mean corpuscular hemoglobin (MCH)  
 Mean cell hemoglobin concentration 
(MCHC)  
 %Reticulocytes  
Clinical Chemistry Blood urea nitrogen (BUN) Aspartate Aminotransferase (AST)/ Serum 
Glutamic-Oxaloacetic Transaminase 
(SGOT) 
 Creatinine Alanine Aminot ransferase (ALT)/ Serum 
Glutamic-Pyruvic Transaminase (SGPT) 
 Glucose Alkaline phosphatase (ALP) 
 Gamma glutamyl transferase (GGT) Creatine kinase  Magnesium Creatine kinase MB fraction will be 
performed if clinically indicated 
 Cholesterol  Chloride  Potassium Globulin 
 Sodium Amylase 
 Calcium Total and direct bilirubin 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 63 Laboratory 
Assessments Parameters 
 Lactate dehydrogenase Conjugated and unconjugated bilirubin will 
be performed if clinically indicated 
 Albumin Total Protein 
 Uric acid Phosphate 
 C-reactive protein Carbon  dioxide (bicarbonate) 
 Triglycerides  
Coagulation International normalized ratio (INR)  Activated partial thromboplastin time 
(APTT)  
 Prothrombin time (PT) Thrombin time  
 Partial prothrombin time Fibrinogen 
Urinalysis Leucocytes Red blood cells 
 Protein pH 
 Bilirubin Nitrite  Urobilinogen Specific gravity 
 Ketones Glucose 
 Microscopy (if clinically indicated)  
Viral serology HIV I and II Hepatitis C Virus 
 HBsAg  Urine drug screen Amphetamine Opiates  
Ethanol Benzodiazepines 
 Cannabinoids Methadone metabolites 
 Cocaine metabolites Barbiturates  Urine creatinine 
Ecstasy (3,4-
Methylenedioxymethamphetamine) 
 Cotinine Phencyclidine  Tricyclin antidepressants (TCA)   
Other screening tests Follicle stimulating hormone (postmenopausal women only)  
Serum or urine human chorionic gonadotropin (hCG) pregnancy test for all women
a 
NOTES: 
a Local urine testing will be standard for the protocol unless serum testing is required by local regulation or 
IRB/IEC. 
 
Investigators must document their revi ew of each laboratory safety report. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 64 Appendix 4 Adverse Events: Definition s and Procedures for Recording, 
Evaluating, Follow-up, and Reporting 
Definition of AE 
AE Definition 
 An AE is any untoward medical occurrence in a subj ect, temporally associated with the use of study 
treatment, whether or not considered  related to the study treatment. 
 NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally asso ciated with the use of 
study treatment. 
 
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, c linical chemistry, or urinalysis) or other safety 
assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from 
baseline, considered clinically significant in the me dical and scientific judgement of the Investigator 
(ie, not related to progression of underlying disease). 
 Exacerbation of a chronic or intermittent pre-existin g condition including either an increase in 
frequency and/or intensity of the condition. 
 Medical occurrences that begin before the start of study treatment but after obtaining informed consent 
will be recorded as pre-treatment-emergen t AEs in the AE section of the eCRF. 
 New conditions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the study. 
 Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae. 
 The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or 
SAE if they fulfill the defi nition of an AE or SAE. Also, "lack of efficacy" or  "failure of expected 
pharmacological action" also constitutes an AE or SAE. 
 
Events NOT Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying dis ease, unless judged by the Inves tigator to be more severe than 
expected for the subject’s condition. 
 The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe than expected for the subject’s condition. 
 Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the 
procedure is the AE. 
 Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital). 
 Anticipated day-to-day fluctuations of pre-existing di sease(s) or condition(s) present or detected at the 
start of the study that do not worsen. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 65 Definition of SAE 
If an event is not an AE per definition above, then  it cannot be an SAE even if serious conditions 
are met (eg, hospitalization for signs/symptoms of the dis ease under study, death due to 
progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose: 
a) Results in death 
b) Is life-threatening 
The term ‘life-threatening’ in the de finition of “serious” refers to an event in which the subject was at risk 
of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe. 
c) Requires inpatient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the subject has been detained (usually involving at least an 
overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hosp italization or fulfills any other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that di d not worsen from baseline is not 
considered an AE. 
d) Results in persistent disability/incapacity 
 The term disability means a substantial disruptio n of a person’s ability to conduct normal life 
functions. 
 This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental  trauma (eg, sprained 
ankle) which may interfere with or  prevent everyday life functions but do not constitute a substantial 
disruption.  
e) Is a congenital anomaly/birth defect 
f) Other situations: 
 Medical or scientific judgement should be exercised in deciding whether SAE reporting is appropriate 
in other situations such as important medical even ts that may not be immediately life-threatening or 
result in death or hospitalization but may jeopardize the subject or may require medical or surgical 
intervention to prevent 1 of the other outcomes listed in the above definition. These events should usually be considered serious. 
Examples of such events include invasive or mali gnant cancers, intensive tr eatment in an emergency 
room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 66 Recording and Follow-up of AE and/or SAE 
AE and SAE Recording 
 When an AE/SAE occurs, it is the responsibility of the Investigator to review all  documentation (eg, 
hospital progress notes, laborato ry reports, and diagnostics reports) related to the event. 
 The Investigator will then record all relevant AE /SAE information in the CRF. Each event must be 
recorded separately. 
 It is not acceptable for the Investigator to  send photocopies of the subject ’s medical records in lieu of 
completion of the AE/SAE CRF page. 
 There may be instances when copies of medical record s for certain cases are requested. In this case, all 
subject identifiers, with the exception of the subject  number, will be redacted on the copies of the 
medical records before submission. 
 The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, th e diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE.  
Assessment of Intensity 
The Investigator will make an assessment of intensity  for each AE and SAE reported during the study and 
assign it to 1 of the following categories:  
 Mild: An event that is easily tolerated by the subj ect, causing minimal discomfort and not interfering 
with everyday activities. 
 Moderate: An event that causes sufficient discomfo rt and interferes with normal everyday activities. 
 Severe: An event that prevents normal everyday activ ities. An AE that is assessed as severe should not 
be confused with a SAE. Severe is a category utilized  for rating the intensity of an event; and both AEs 
and SAEs can be assessed as severe. 
An event is defined as ‘serious’ when it meets at l east 1 of the predefined outcomes as described in the 
definition of an SAE, NOT when it is rated as severe. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 67 Assessment of Causality 
The Investigator must assess the causality of an AE (including SAEs) to the use of a study drug using a 
2-category scale (not related, or related) based on c linical judgement and using all available information, 
and may include consideratio n of the following factors: 
 Possible alternative causes of the AE, including th e disease under treatment, pre-existing conditions, 
concomitant use of other drugs, and presence of environmental or genetic factors. 
 The temporal association between drug  exposure and onset of the AE.  
 Whether the manifestations of the AE are consis tent with known actions or toxicity of the 
investigational product. 
 Whether the AE resolved or improved with stoppi ng use of the investigational product. Judgement 
should be used if multiple products are discontinued at the same time. 
 Positive rechallenge. 
 Positive dechallenge (resolution upon stopping suspect the IP, in absence of other intervention or 
treatment). 
 The causal relationship between at study drug and the AE will be assessed using one of the following 
categories: 
o Not Related : An AE is not associated with study me dication if no causal relationship exists 
between the IP and the AE, but an obvious alternative cause exists, eg, the subject’s 
underlying medical condition or concomitant therapy.  
o Related : An AE is attributed to the study medi cation if there is reasonable/plausible 
possibility that the AE may have been caused by the IP.  
 
Follow-up of AEs and SAEs 
 The Investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested to elucidate the nature and/or causality of the 
AE or SAE as fully as possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals. 
 New or updated information will be reco rded in the originally completed CRF. 
 The Investigator will submit any updated SAE data to  the Sponsor within 24 hours of receipt of the 
information.  
 
Reporting of SAEs 
SAE Reporting via an Electro nic Data Collection Tool 
 The primary mechanism for reporting an SAE will be the electronic data collection tool. 
 If the electronic system is unavailable for more than 24 hours, then the study center will use the paper 
SAE data collection tool (see next section). 
 The study center will enter the SAE data into the el ectronic system as soon as it becomes available. 
 After the study is completed at a given study center,  the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data. 
 If a study center receives a report of a new SAE from a subject or recei ves updated data on a 
previously reported SAE after the electronic data coll ection tool has been taken off-line, then the study 
center can report this information on a paper SAE form (see next section) or to the Medical 
Monitor/SAE coordinator by telephone. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 68 SAE Reporting via Paper CRF 
 Facsimile transmission of the SAE paper CRF is the preferred method to transmit this information to 
the Medical Monitor or the SAE coordinator. 
 In rare circumstances and in the absence of f acsimile equipment, notification by telephone is 
acceptable with a copy of the SAE data collection to ol sent by overnight mail or courier service. 
 Initial notification via telephone does not  replace the need for the Investig ator to complete and sign the 
SAE CRF pages within the desi gnated reporting time frames. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 69 Appendix 5 Excluded Medications/Therapy 
The following medications are prohibited  throughout the duration of the study: 
 Medications (either topically or systemically) for a conditi on related to ear or nose. 
 Anti-cholinergic medications (eg, anti-histamine, anti-nausea). 
 Any prescription drug (except oral contraceptives, See Appendix 6 ). 
 Administration of any intranasal product other than the Investigational Product. 
 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 70 Appendix 6 Contraceptive Guidance and Collection of Pregnancy 
Information 
Definitions: 
Woman of childbearing potential (WOCBP) 
A woman is considered fertile following mena rche and until becoming postmenopausal unless 
permanently sterile (see below). 
Women in the following categories are not considered WOCBP 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
a) Documented hysterectomy. 
b) Documented bilateral salpingectomy. 
c) Documented bilate ral oophorectomy. 
Note: Documentation can come from the study cen ter personnel’s: review of the subject’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female: 
a) A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. A high follicle stimulating hor mone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopa usal state in women not using hormonal 
contraception or hormonal replacement ther apy (HRT). However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient.  
b) Females on HRT and whose menopausal status is in doubt will be required to use 1 of the 
non-estrogen hormonal highly effect ive contraception methods if  they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before study enrollment. 
Contraception Guidance 
Male  subjects  
 Male subjects with female partners of childbearin g potential are eligible to participate if they 
agree to ONE of the following:  
 Are abstinent from penile-vaginal intercourse  as their usual and preferred lifestyle 
(abstinent on a long-term and persistent basis) and agree to remain abstinent for 
duration of study. 
 Agree to use a male condom and have th eir partner use of a contraceptive method 
with a failure rate of <1% per year as described in the table below when having 
penile-vaginal intercourse with a WO CBP who is not currently pregnant. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 71  In addition, male subjects must refrain from donating sperm for the duration of the study and 
for 90 days following the last administration of study treatment. 
 Male subjects with a pregnant or breastfeedi ng partner must agree to remain abstinent from 
penile-vaginal intercou rse or use a male condo m during each episode of  penile penetration. 
Female subjects 
Female subjects of childbearing potential are eligib le to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described in the table below for 
the duration of the study and for 30 days fo llowing the last dose  of study treatment. 
Highly Effective Contraceptive Methods 
Highly Effective Contraceptive Methods That Are User Dependent a  
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen and progestogen cont aining) hormonal contr aception associated with inhibition of ovulationb  
 Oral.  
 Intravaginal.  
 Transdermal. 
Progestogen only hormonal contraception as sociated with inhi bition of ovulation 
 Oral. 
 Injectable.  
Highly Effective Methods That Are User Independent a  
Implantable progestogen only ho rmonal contraception associated with inhibition of ovulationb 
 Intrauterine device (IUD). 
 Intrauterine hormone-releasing system (IUS). 
Bilateral tubal occlusion. 
Vasectomized Partner  
A vasectomized partner is a highly effective birth control method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used.  
Sexual Abstinence  
Sexual abstinence is considered a highly effective meth od only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.   
NOTES:  
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive meth ods for subjects participating in clinical studies.  
b Hormonal contraception may be suscep tible to interactio n with the study treatment, which may reduce the efficacy 
of the contraceptive method. In this case, 2 highly effec tive methods of contraception should be utilized during 
the treatment period.  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 72 Pregnancy Testing: 
 WOCBP should only be included after a negative highly sensitive urine or serum pregnancy 
test. 
 Additional pregnancy testing should be pe rformed at times sp ecified in the SoA  during the 
treatment period. 
Pregnancy testing will be performed  whenever a menstrual cycle is  missed or when pregnancy is 
otherwise suspected.  
Collection of Pregnancy Information 
Male subjects with partners who become pregnant  
 The Investigator will attempt to collect pregna ncy information on any ma le subject’s female 
partner who becomes pregnant wh ile the male subject is in th is study. This applies only to 
male subjects who receive study treatment. 
 After obtaining the necessary signed informed consent from the pre gnant female partner 
directly, the Investigator will record pregna ncy information on the appropriate form and 
submit it to the Sponsor within 24 hours of l earning of the partner’s pregnancy. The female 
partner will also be followed to determine the outcome of th e pregnancy. Information on the 
status of the mother and child  will be forwarded to the Spons or. Generally, the follow-up will 
be no longer than 6 to 8 weeks following the es timated delivery date. A ny termination of the 
pregnancy will be reported regardless of fetal st atus (presence or absence of anomalies) or 
indication for th e procedure.  
Female Subjects who become pregnant  
 The Investigator will collect pregnancy information on any female subject who becomes 
pregnant while particip ating in this study. Information will be recorded on the appropriate 
form and submitted to the Sponsor within 24 hours of lear ning of a subject’s pregnancy. The 
subject will be followed to determine the out come of the pregnancy. The Investigator will 
collect follow-up information on the subject a nd the neonate and the information will be 
forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 
weeks beyond the estimated delivery date. Any te rmination of pregnancy will be reported, 
regardless of fetal status (presence or absence of anomalies) or indicat ion for the procedure. 
 While pregnancy itself is not considered to be  an AE or SAE, any pr egnancy complication or 
elective termination of a pre gnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. 
 Any post-study pregnancy related SAE considered  reasonably related to the study treatment 
by the Investigator will be reported to  the Sponsor as described in Section 8.3.4 . While the 
Investigator is not obligated to  actively seek this information in former subjects, he or she 
may learn of an SAE through spontaneous reporting.  
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 73  Any female subject who becomes pregnant while participating in the study will be withdrawn 
from the study. 
Continuation of study treatment ma y only be allowed if either of the following cr iteria is met: 
The study treatment has an approve d label that indicates it can be used safely in pregnant 
females.  
OR  
All of the following apply:  
 The subject has a high mortality disease.  
 The Investigator determines the subject is bene fitting from study partic ipation and there is no 
other reasonable tr eatment for her. 
 The Sponsor and the relevant I RB/IEC give written approval. 
 The subject gives signed  informed consent. 
 The Investigator agrees to monitor the outcome of the pregnancy and the status of the subject 
and her offspring. 
 The protocol is amended to allow such pa rticipation on a case-by-case basis, if such 
participation is not already addressed in the protocol. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 74 Appendix 7 Device Experience Questionnaire 
 

CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 75  

CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 76 Appendix 8 Liver Safety: Suggested Actions and Follow-up Assessments  
Not applicable. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 77 Appendix 9 Medical Device Incidents : Definition and Procedures for 
Recording, Evaluating, Follow-up, and Reporting  
Definitions of a Medic al Device Incident 
The detection and documentation pr ocedures described in this pr otocol apply to all Sponsor 
medical devices provided for use in the study (see Section 6.1) for the list of Sponsor medical 
devices). 
Medical Device Incident definition 
 A Medical Device Incident is a ny malfunction or deterioration in  the characteristics and/or 
performance of a device as well as any inadequacy  in the labeling or the instructions for use 
which, directly or indirectl y, might lead to or might ha ve led to the death of a 
subject/user/other pers on or to a serious deteriorati on in his/her state of health. 
 Not all incidents lead to death or serious deterioration in heal th.  The nonoccurrence of such 
a result might have been due to other fortunate circumstances or to the intervention of health 
care personnel. 
It is sufficient that: 
 An incident  associated with a device happened. 
 AND 
 
 The incident  was such that, if it occurred again, might lead to death or a serious deterioration 
in health. 
A serious deterioration in state of hea lth can include any of the following: 
 Life-threatening illness. 
 Permanent impairment of body function or  permanent damage to body structure. 
 Condition necessitating medical or surgical intervention to prevent 1 of the above. 
 Fetal distress, fetal death, or any congenital abnormality or birth defects. 
Examples of incidents 
 A subject, user, caregiver, or hea lthcare professional is injured as  a result of a medical device 
failure or its misuse. 
 A subject’s study treatment is interrupted or compromised by  a medical device failure. 
 A misdiagnosis due to medical device failure leads to inappropriate treatment. 
 A subject’s health deteriorates  due to medical device failure. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 78 Documenting Medical Device Incidents 
Medical Device Incident documenting 
 Any Medical Device Incident oc curring during the study will be  documented in the subject’s 
medical records, in accordance with the Investigator’s normal clinical practice, and on the appropriate form of the CRF. 
 For incidents fulfilling the definition of an AE  or an SAE, the appropriate AE/SAE CRF page 
will be completed as described in Appendix 4 . 
 The CRF will be completed as thoroughly as pos sible and signed by the Investigator before 
transmittal to the Sponsor or designee. 
 It is very important that the I nvestigator provides his/her assess ment of causality (relationship 
to the medical device provided by the Sponsor)  at the time of the initial AE or SAE report 
and describes any corrective or remedial actions  taken to prevent recu rrence of the incident. 
A remedial action is any action other than routin e maintenance or servicin g of a medical device 
where such action is necessary to prevent re currence of an incident. This includes any 
amendment to the device design to prevent recurrence. 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 79 Appendix 10 Audiology Testing Template 

CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 80 Appendix 11 Protocol Amendment History 
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Tabl e of Contents (TOC). 
CONFIDENTIAL Protocol OP0201-C-002  - Amendment 1 
 81 Appendix 12 Signature of Investigator 
PROTOCOL TITLE:  Evaluation of  safety of repeated doses of OP0201 metered dose inhaler 
compared to placebo in healthy adult volunteers 
PROTOCOL NO: OP0201-C-002 
VERSION:   Amendment 1  
This protocol is a confidential communication of the Sponsor. I c onfirm that I have read this 
protocol, I understand it, and I will work according to this protocol. I will also work consistently 
with the ethical principles that have their orig in in the Declaration of  Helsinki and that are 
consistent with GCPs and the applicable laws and regulations. Acceptance of this document 
constitutes my agreement that no unpublished information contained herein will be published or 
disclosed without prior writt en approval from the Sponsor. 
Instructions to the Investigator:  Please SIGN and DATE this si gnature page. PRINT your name, ti tle, and the name of the study 
center in which the study will be conducted. Return the signed copy to Sponsor or CRO. 
 
I have read this protocol in its entirety and agree to  conduct the study accordingly: 
 
Signature of Investigator: __________________________            Date:  ________ Printed Name:                         __________________________ 
Investigator Title:                    __________________________ 
 Name/Address of Center:       __________________________ 
    __________________________ 
    __________________________ 